Tablet formulations

Abstract

The present disclosure relates to pharmaceutical compositions (e.g., tablets) comprising an human immunodeficiency virus (HIV) capsid inhibitor and a nucleoside reverse transcriptase translocation inhibitor (NRTTI), useful for the treatment of an HIV infection in a patient.

Description

[0001] PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0002] 1572-WO-PCT / 35648-0367WO1 PATENT

[0003] Tablet Formulations

[0004] TECHNICAL FIELD

[0005] The present disclosure relates to pharmaceutical compositions (e.g., tablets) comprising an HIV capsid inhibitor and a nucleoside reverse transcriptase translocation inhibitor (NRTTI), which are useful for the treatment of a human

[0006] 5 immunodeficiency virus (HIV) infection in a patient.

[0007] BACKGROUND

[0008] Advances in combination antiretroviral therapy (ART) for HIV have led to significant improvements in morbidity and mortality by suppressing viral replication,

[0009] 10 preserving immunologic function, and averting disease progression to AIDS. Standard of care for the treatment of HIV- 1 infection involves the use of a combination of ARV drugs to suppress viral replication to below detectable limits, increase CD4+ T-cell counts, and delay disease progression.

[0010] While currently available combination ART for the treatment of HIV- 1 infection is efficacious and well tolerated, all current oral regimens require daily adherence to minimize the emergence of drug resistant variants. In addition, “treatment fatigue” can occur, defined as “decreased desire and motivation to maintain vigilance in adhering to a treatment regimen” among people with HIV-1 (PWH) prescribed chronic or life-long treatment (see e.g., Clabom et al, Psychol.

[0011] 20 Health Med. 2015;20 (3): 1-11), which can lead to nonadherence and treatment failure. As such, there remains a significant medical need for ARVs that can be administered less frequently (z.e., long acting drug products), thereby providing alternative treatment options for PWH.

[0012] 25 SUMMARY

[0013] The present application provides, inter alia, a tablet comprising a compound of Formula la: PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0014] 1572-WO-PCT / 35648-0367WO1 PATENT la or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; a compound of Formula Ila:

[0015] 5

[0016] Ila or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients

[0017] The present disclosure further provides a method of treating HIV in a patient,

[0018] 10 comprising administering to the patient a tablet provided herein.

[0019] The present disclosure further provides a tablet provided herein, for use in any of the methods described herein.

[0020] The present disclosure further provides use of a tablet provided herein, for the preparation of a medicament for use in any of the methods described herein.

[0021] DESCRIPTION OF DRAWINGS

[0022] FIGs. 1A-1B show mean (SD) islatravir (ISL) plasma concentration-time profiles by cohort. The horizontal reference line indicates the lower limit of quantitation (LLOQ), defined as 0.02 ng / mL for ISL. Value below the limit of

[0023] 20 quantitation were treated as 0 for pre-dose and post-dose summary statistics.

[0024] FIG. 2 shows mean (SD) islatravir (ISL) plasma concentration-time profiles (through 24-hour time after dose on Day 1) by cohort. The horizontal reference line PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0025] 1572-WO-PCT / 35648-0367WO1 PATENT indicates the lower limit of quantitation (LLOQ), defined as 0.02 ng / mL for ISL. Value below the limit of quantitation were treated as 0 for pre-dose and post-dose summary statistics.

[0026] FIGs. 3 A-3B show mean (SD) lenacapavir (LEN) plasma concentration-time

[0027] 5 profiles by cohort. The horizontal reference line indicates the lower limit of quantitation (LLOQ), defined as 0.1 ng / mL for LEN. Value below the limit of quantitation were treated as 0 for pre-dose and post-dose summary statistics.

[0028] FIG. 4 shows mean (SD) lenacapavir (LEN) plasma concentration-time profiles (through 24-hour time after dose on Day 1) by cohort. The horizontal reference line indicates the lower limit of quantitation (LLOQ), defined as 0.1 ng / mL for LEN. Value below the limit of quantitation were treated as 0 for pre-dose and postdose summary statistics.

[0029] FIGs. 5A-5B show representative schemes for preparing the fixed-dose combination (FDC) tablets of Examples 1-2.

[0030] 15 FIG. 6 shows a representative scheme for preparing the lenacapavir spray dried dispersion (LEN SDD) described in Example 3.

[0031] FIGs. 7A-7B show structural PopPK models for ISL (FIG. 7A) and LEN (FIG. 7B).

[0032] FIG. 8 shows simulated dosing scenarios of ISL and LEN. Dosing scenarios

[0033] 20 under steady-state conditions following missed oral QW doses (Scenarios 2a-4) were compared against the reference scenario of no missed doses (Scenario 1), as well as efficacy and clinically established safety exposure thresholds, as appropriate.

[0034] FIGs. 9A-9E show dose simulation plots for ISL under simulated dosing Scenario 1 (FIG. 9A), Scenario 2a (FIG. 9B), Scenario 2b (FIG. 9C), Scenario 3 (FIG. 9D), and Scenario 4 (FIG. 9E). Left-most arrow indicates a missed dose; right most arrow(s) indicate the next dose(s) taken (e.g., in Scenario 4, the leftmost two arrows indicate missed dose and the rightmost two arrows indicate the next dose(s) taken).aMaintenance FDC (2 mg ISL) was used for Scenarios 2a, 2b, and 3.bStarting FDC (1 mg ISL) was used for Scenario 4.

[0035] 30 FIGs. 10A-10E show dose simulation plots for LEN under simulated dosing Scenario 1 (FIG. 10A), Scenario 2a (FIG. 10B), Scenario 2b (FIG. 10C), Scenario 3 (FIG. 10D), and Scenario 4 (FIG. 10E). Left-most arrow indicates a missed dose; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0036] 1572-WO-PCT / 35648-0367WO1 PATENT right-most arrow(s) indicate the next dose(s) taken (e.g., in Scenario 4, the leftmost two arrows indicate missed dose and the rightmost two arrows indicate the next dose(s) taken).aMaintenance FDC (300 mg LEN) was used for Scenarios 2a, 2b, and 3.bStarting FDC (600 mg LEN) was used for Scenario 4.

[0037] 5

[0038] DETAILED DESCRIPTION

[0039] Lenacapavir (LEN), a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor, has the potential to provide an additional option for populations at risk of HIV acquisition. Lenacapavir can help address substantial existing PrEP barriers

[0040] 10 including 1) requirement for daily adherence, 2) stigma and concerns about disclosure and discrimination or other social harms, 3) oral medication-associated adverse events (AEs), including gastrointestinal tolerability, and 4) challenges with access to health care providers in overburdened health systems or in geographical PrEP deserts. Thus, LEN has the potential to increase the uptake of, adherence to, and thereby the scalability of PrEP, thus contributing to the overarching goal of ending the HIV-1 epidemic.

[0041] As used herein, the term “lenacapavir” or “LEN” refers to the compound N- ((S)-l-(3-(4-chloro-3-(methylsulfonamido)-l-(2,2,2-trifluoroethyl)-lH-indazol-7-yl)- 6-(3 -methyl-3 -(methyl sulfonyl)but- 1 -yn- 1 -yl)pyridin-2-yl)-2-(3 , 5 -

[0042] 20 difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5- tetrahydro- lH-cyclopropa[3 ,4]cy clopentaf 1 ,2-c]pyrazol- 1 -yl)acetamide, having the following structure: PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0043] 1572-WO-PCT / 35648-0367WO1 PATENT

[0044] Islatravir (ISL) is a novel deoxyadenosine analog with potent ARV activity, including activity against common nucleoside reverse transcriptase inhibitor-resistant variants, and favorable nonclinical toxicity and pharmacokinetic (PK) profiles. ISL is converted intracellularly to the active ISL-triphosphate (ISL-TP) that potently inhibits

[0045] 5 HIV-1 replication by preventing translocation of reverse transcriptase on the viral primer template. Lenacapavir (LEN) is a novel, first-in-class, multistage selective inhibitor of HIV-1 capsid function. It inhibits HIV-1 at multiple points in the viral lifecycle, including interfering with capsid-mediated nuclear uptake of preintegration complexes and impairing virion production and proper capsid core formation. It has 2 dosage forms (oral tablets for initial loading and 6-monthly subcutaneous injection) both of which are approved in adults in combination with other ARVs for the treatment of multidrug resistant HIV-1 infection in several countries. Oral administration of ISL and LEN as a 2-drug combination regimen has the potential to offer a safe, efficacious, and well tolerated once-weekly regimen for the treatment of

[0046] 15 PWH.

[0047] As used herein, the term “islatravir” or “ISL” refers to 4'-ethynyl-2-fluoro-2'- deoxyadenosine (i.e., (27?,35',57?)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2- (hydroxymethyl)tetrahydrofuran-3-ol), having the following structure: islatravir

[0048] One skilled in the art understands that a compound structure may be named or identified using commonly recognized nomenclature systems and symbols. By way of example, the compound may be named or identified with common names, systematic or non-systematic names. The nomenclature systems and symbols that are commonly

[0049] 25 recognized in the art of chemistry including but not limited to Chemical Abstract Service (CAS) and International Union of Pure and Applied Chemistry (IUPAC).

[0050] Pharmaceutical Compositions PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0051] 1572-WO-PCT / 35648-0367WO1 PATENT

[0052] Accordingly, the present application provides a tablet comprising a compound of Formula la: la

[0053] 5 or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; a compound of Formula Ila:

[0054] Ila or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof;

[0055] 10 and one or more pharmaceutically acceptable excipients.

[0056] In some embodiments, the tablets disclosed herein consist essentially of the components described herein. In some embodiments, the tablets disclosed herein consist of the components described herein.

[0057] Tablets of the disclosure are formulated so as to allow the active ingredients contained therein to be bioavailable upon administration of the tablet to a patient. The tablet to be administered will, in any event, contain a therapeutically effective amount of the compound of Formula la or lb and the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, for treating an HIV infection as described herein. In some embodiments, the tablet

[0058] 20 provided herein is suitable for oral administration. In some embodiments, the tablet provided herein is a fixed-dose combination tablet (z.e., a fixed dose combination of PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0059] 1572-WO-PCT / 35648-0367WO1 PATENT the compound of Formula la or lb and the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof).

[0060] In some embodiments, the compound of Formula la or lb is administered as a salt, such as a pharmaceutically acceptable salt. A salt generally refers to a derivative

[0061] 5 of a disclosed compound wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. A pharmaceutically acceptable salt is one that, within the scope of sound medical judgment, is suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines, alkali or organic salts of acidic residues such as carboxylic acids, and the like. The pharmaceutically acceptable salts of the present disclosure include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic

[0062] 15 inorganic or organic acids. The pharmaceutically acceptable salts of the present disclosure can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid. Lists of suitable salts are found

[0063] 20 in Remington ’s Pharmaceutical Sciences, 17thed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety. In some embodiments, the salt is a sodium salt. In some embodiments, the pharmaceutically acceptable salt of the compound of Formula la or lb provided herein is a sodium salt. In some embodiments, the pharmaceutically acceptable salt of the compound of Formula lb provided herein is a sodium salt.

[0064] In some embodiments, the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof (e.g., lenacapavir sodium) is present in a tablet provided herein as a spray dried dispersion

[0065] 30 (SDD).

[0066] In some embodiments, the tablet comprises a spray dried dispersion (SDD) of the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0067] 1572-WO-PCT / 35648-0367WO1 PATENT solvate, or combination thereof. In some embodiments, the tablet comprises a spray dried dispersion (SDD) of the compound of Formula la, or a pharmaceutically acceptable salt thereof. In some embodiments, the tablet comprises a spray dried dispersion (SDD) of the sodium salt of the compound of Formula la.

[0068] 5 In some embodiments, the tablet comprises a spray dried dispersion (SDD) of the compound of Formula lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof. In some embodiments, the tablet comprises a spray dried dispersion (SDD) of the compound of Formula lb, or a pharmaceutically acceptable salt thereof. In some embodiments, the tablet comprises a spray dried dispersion (SDD) of the sodium salt of the compound of Formula lb (z.e., “the lenacapavir spray dried dispersion” or “LEN SDD” or “lenacapavir spray dried dispersion”).

[0069] In some embodiments, the spray dried dispersion comprises the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or

[0070] 15 combination thereof, copovidone, and poloxamer 407.

[0071] In some embodiments, the spray dried dispersion comprises the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, copovidone, and poloxamer 407. In some embodiments, the spray dried dispersion comprises the compound of Formula la, or a pharmaceutically acceptable

[0072] 20 salt thereof, copovidone, and poloxamer 407. In some embodiments, the spray dried dispersion comprises the sodium salt of the compound of Formula la, copovidone, and poloxamer 407.

[0073] In some embodiments, the spray dried dispersion comprises the compound of Formula lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, copovidone, and poloxamer 407. In some embodiments, the spray dried dispersion comprises the compound of Formula lb, or a pharmaceutically acceptable salt thereof, copovidone, and poloxamer 407. In some embodiments, the spray dried dispersion comprises the sodium salt of the compound of Formula lb, copovidone, and poloxamer 407.

[0074] 30 In some embodiments, the spray dried dispersion comprises about 76 w / w% to about 77 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, about 18 w / w% to about PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0075] 1572-WO-PCT / 35648-0367WO1 PATENT

[0076] 19 w / w% copovidone, and about 4 w / w% to about 6 w / w% pol oxamer 407. In some embodiments, the spray dried dispersion comprises about 76 w / w% to about 77 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, about 18 w / w% to about 19 w / w% copovidone, and about 4 w / w% to about 6 w / w%

[0077] 5 poloxamer 407. In some embodiments, the spray dried dispersion comprises about 76 w / w% to about 77 w / w% of the sodium salt of the compound of Formula la or lb, about 18 w / w% to about 19 w / w% copovidone, and about 4 w / w% to about 6 w / w% poloxamer 407. In some embodiments, the spray dried dispersion comprises about 76 w / w% to about 77 w / w% of the sodium salt of the compound of Formula la, about 18 w / w% to about 19 w / w% copovidone, and about 4 w / w% to about 6 w / w% poloxamer 407. In some embodiments, the spray dried dispersion comprises about 76 w / w% to about 77 w / w% of the sodium salt of the compound of Formula lb, about 18 w / w% to about 19 w / w% copovidone, and about 4 w / w% to about 6 w / w% poloxamer 407.

[0078] In some embodiments, the spray dried dispersion comprises about 76.7 w / w%

[0079] 15 of the compound of Formula la or lb, or a pharmaceutically acceptable salt, cocrystal, solvate, or combination thereof, about 18.3 w / w% copovidone, and about 5.0 w / w% poloxamer 407. In some embodiments, the spray dried dispersion comprises about 76.7 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, about 18.3 w / w% copovidone, and about 5.0 w / w%

[0080] 20 poloxamer 407. In some embodiments, the spray dried dispersion comprises about 76.7 w / w% of the sodium salt of the compound of Formula la or lb, about 18.3 w / w% copovidone, and about 5.0 w / w% poloxamer 407. In some embodiments, the spray dried dispersion comprises about 76.7 w / w% of the sodium salt of the compound of Formula la, about 18.3 w / w% copovidone, and about 5.0 w / w% poloxamer 407. In some embodiments, the spray dried dispersion comprises about 76.7 w / w% of the sodium salt of the compound of Formula lb, about 18.3 w / w% copovidone, and about 5.0 w / w% poloxamer 407.

[0081] As used herein, the terms “lenacapavir spray dried dispersion” and “LEN SDD” refers to the spray dried dispersion described in Table 17.

[0082] 30 As used herein, the term “co-crystal” refers to a crystalline material formed by combining a compound (e.g., a compound of Formula la, lb, Ila, or lib) or any Formula disclosed herein and one or more co-crystal formers (z.e., a molecule, ion, or PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0083] 1572-WO-PCT / 35648-0367WO1 PATENT atom). In certain instances, co-crystals may have improved properties as compared to the parent form (z.e., the free molecule, zwitterion, etc.) or a salt of the parent compound. Improved properties can be increased solubility, increased dissolution, increased bioavailability, increased dose response, decreased hygroscopicity, a

[0084] 5 crystalline form of a normally amorphous compound, a crystalline form of a difficult to salt or unsaltable compound, decreased form diversity, more desired morphology, and the like. Methods for making and characterizing co-crystals are known to those of skill in the art.

[0085] As used herein, the term “hydrate” refers to the complex formed by the combining of a compound (e.g., a compound of Formula Ila or lib) or any Formula disclosed herein, and water.

[0086] As used herein, the term “solvate” refers to a complex formed by combining a compound (e.g., a compound of Formula Ila or lib) or any other Formula as disclosed herein, and a solvent or a crystalline solid containing amounts of a solvent

[0087] 15 incorporated within the crystal structure. As used herein, the term “solvate” includes hydrates.

[0088] Any formula or structure given herein, including Formulas la, lb, Ila, or lib, is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas

[0089] 20 given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as, but not limited to2H (deuterium, D),3H (tritium),nC,13C,14C,15N,18F,31P,32P,35S,36C1 and125I. Various isotopically labeled compounds of the present disclosure, for example those into which radioactive isotopes such as3H,13C and14C are incorporated. Such isotopically labeled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue

[0090] 30 distribution assays or in radioactive treatment of patients. PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0091] 1572-WO-PCT / 35648-0367WO1 PATENT

[0092] The modifier “about” used in connection with a quantity is inclusive of the stated value and has the meaning dictated by the context (e.g., includes the degree of error associated with measurement of the particular quantity).

[0093] Except as otherwise noted, the methods and techniques of the present

[0094] 5 disclosure are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See, e.g., Loudon, Organic Chemistry, 5thedition, New York: Oxford University Press, 2009; Smith, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 7thedition, Wiley-Interscience, 2013.

[0095] Compounds as described herein can be purified by any of the means known in the art, including chromatographic means, such as high performance liquid chromatography (HPLC), preparative thin layer chromatography, flash column chromatography, supercritical fluid chromatography (SFC), and ion exchange

[0096] 15 chromatography. Any suitable stationary phase can be used, including normal and reversed phases as well as ionic resins. Most typically the disclosed compounds are purified via silica gel and / or alumina chromatography. See, e.g., Introduction to Modern Liquid Chromatography, 2nded., ed. L. R. Snyder and J. J. Kirkland, John Wiley and Sons, 1979; and Thin Layer Chromatography, E. Stahl (ed.), Springer-

[0097] 20 Verlag, New York, 1969.

[0098] As used herein, “pharmaceutically acceptable carrier” is meant to refer to any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.

[0099] In some embodiments, the tablet comprises the compound of Formula la, or a pharmaceutically acceptable salt thereof. In some embodiments, the tablet comprises a pharmaceutically acceptable salt of the compound of Formula la. In some

[0100] 30 embodiments, the tablet comprises a sodium salt of the compound of Formula la. PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0101] 1572-WO-PCT / 35648-0367WO1 PATENT

[0102] In some embodiments, the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, is a compound of Formula lb:

[0103] 5 lb or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[0104] In some embodiments, the tablet comprises the compound of Formula Ila, or a pharmaceutically acceptable salt thereof. In some embodiments, the tablet comprises a pharmaceutically acceptable salt of the compound of Formula lb. In some

[0105] 10 embodiments, the tablet comprises a sodium salt of the compound of Formula lb.

[0106] In some embodiments, the tablet comprises a compound of Formula Ila, or a solvate thereof. In some embodiments, the tablet comprises a solvate of the compound of Formula Ila. In some embodiments, the tablet comprises a hydrate of the compound of Formula Ila. In some embodiments, the tablet comprises a monohydrate of the compound of Formula Ila.

[0107] In some embodiments, the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, is a compound of Formula lib:

[0108] 20 PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0109] 1572-WO-PCT / 35648-0367WO1 PATENT or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof. In some embodiments, the tablet comprises a compound of Formula lib, or a solvate thereof. In some embodiments, the tablet comprises a solvate of the compound of Formula lib. In some embodiments, the tablet comprises a hydrate of the compound

[0110] 5 of Formula lib. In some embodiments, the tablet comprises a monohydrate of the compound of Formula lib.

[0111] In some embodiments, the tablet comprises about 18 w / w% to about 30 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt, cocrystal, solvate, or combination thereof, for example, about 18 w / w%, about 19 w / w%, about 20 w / w%, about 20.1 w / w%, about 20.2 w / w%, about 20.3 w / w%, about 20.4 w / w%, about 20.5 w / w%, about 20.6 w / w%, about 20.7 w / w%, about 20.8 w / w%, about 20.9 w / w%, about 21 w / w%, about 22 w / w%, about 23 w / w%, about 24 w / w%, about 25 w / w%, about 26 w / w%, about 27 w / w%, about 28 w / w%, about 29 w / w%, or about 30 w / w% of the compound of Formula la or lb, or a pharmaceutically

[0112] 15 acceptable salt, co-crystal, solvate, or combination thereof.

[0113] In some embodiments, the tablet comprises about 20 w / w% to about 30 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, for example, about 20 w / w%, about 21 w / w%, about 22 w / w%, about 23 w / w%, about 24

[0114] 20 w / w%, about 25 w / w%, about 26 w / w%, about 27 w / w%, about 28 w / w%, about 29 w / w%, or about 30 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof. In some embodiments, the tablet comprises about 26 w / w% to about 27 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof. In some embodiments, the tablet comprises about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof. In some embodiments, the tablet comprises about 26.67 w / w% of the spray dried dispersion of the compound of

[0115] 30 Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof. PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0116] 1572-WO-PCT / 35648-0367WO1 PATENT

[0117] In some embodiments, the tablet comprises about 20 w / w% to about 30 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, for example, about 20 w / w%, about 21 w / w%, about 22 w / w%, about 23 w / w%, about 24 w / w%, about 25 w / w%, about 26

[0118] 5 w / w%, about 27 w / w%, about 28 w / w%, about 29 w / w%, or about 30 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof. In some embodiments, the tablet comprises about 26 w / w% to about 27 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof. In some embodiments, the tablet comprises about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof. In some embodiments, the tablet comprises about 26.67 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof.

[0119] In some embodiments, the tablet comprises about 20 w / w% to about 30 w / w%

[0120] 15 of the spray dried dispersion of the sodium salt of the compound of Formula la or lb, for example, about 20 w / w%, about 21 w / w%, about 22 w / w%, about 23 w / w%, about 24 w / w%, about 25 w / w%, about 26 w / w%, about 27 w / w%, about 28 w / w%, about 29 w / w%, or about 30 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la or lb. In some embodiments, the tablet comprises about

[0121] 20 26 w / w% to about 27 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la or lb. In some embodiments, the tablet comprises about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la or lb. In some embodiments, the tablet comprises about 26.67 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la or lb.

[0122] In some embodiments, the tablet comprises about 20 w / w% to about 30 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la, for example, about 20 w / w%, about 21 w / w%, about 22 w / w%, about 23 w / w%, about 24 w / w%, about 25 w / w%, about 26 w / w%, about 27 w / w%, about 28 w / w%, about 29

[0123] 30 w / w%, or about 30 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la. In some embodiments, the tablet comprises about 26 w / w% to about 27 w / w% of the spray dried dispersion of the sodium salt of the compound of PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0124] 1572-WO-PCT / 35648-0367WO1 PATENT

[0125] Formula la. In some embodiments, the tablet comprises about 26.6 w / w% to about

[0126] 26.7 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la. In some embodiments, the tablet comprises about 26.67 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la.

[0127] 5 In some embodiments, the tablet comprises about 20 w / w% to about 30 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula lb, for example, about 20 w / w%, about 21 w / w%, about 22 w / w%, about 23 w / w%, about 24 w / w%, about 25 w / w%, about 26 w / w%, about 27 w / w%, about 28 w / w%, about 29 w / w%, or about 30 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula lb. In some embodiments, the tablet comprises about 26 w / w% to about 27 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula lb. In some embodiments, the tablet comprises about 26.6 w / w% to about

[0128] 26.7 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula lb. In some embodiments, the tablet comprises about 26.67 w / w% of the

[0129] 15 spray dried dispersion of the sodium salt of the compound of Formula lb.

[0130] In some embodiments, the tablet comprises about 20 w / w% to about 30 w / w% of the lenacapavir spray dried dispersion as described herein, for example, about 20 w / w%, about 21 w / w%, about 22 w / w%, about 23 w / w%, about 24 w / w%, about 25 w / w%, about 26 w / w%, about 27 w / w%, about 28 w / w%, about 29 w / w%, or about

[0131] 20 30 w / w% of the lenacapavir spray dried dispersion. In some embodiments, the tablet comprises about 26 w / w% to about 27 w / w% of the lenacapavir spray dried dispersion. In some embodiments, the tablet comprises about 26.6 w / w% to about

[0132] 26.7 w / w% of the lenacapavir spray dried dispersion. In some embodiments, the tablet comprises about 26.67 w / w% of the lenacapavir spray dried dispersion.

[0133] In some embodiments, the tablet comprises about 18 w / w% to about 30 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, for example, about 18 w / w%, about 19 w / w%, about 20 w / w%, about 21 w / w%, about 22 w / w%, about 23 w / w%, about 24 w / w%, about 25 w / w%, about 26 w / w%, about 27 w / w%, about 28 w / w%, about 29 w / w%, or about 30 w / w% of the

[0134] 30 compound of Formula la or lb, or a pharmaceutically acceptable salt thereof. In some embodiments, the tablet comprises about 19 w / w% to about 21 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof. In some PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0135] 1572-WO-PCT / 35648-0367WO1 PATENT embodiments, the tablet comprises about 19.8 w / w% to about 20.8 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof.

[0136] In some embodiments, the tablet comprises about 18 w / w% to about 30 w / w% of the sodium salt of the compound of Formula la or lb, for example, about 18 w / w%,

[0137] 5 about 19 w / w%, about 20 w / w%, about 21 w / w%, about 22 w / w%, about 23 w / w%, about 24 w / w%, about 25 w / w%, about 26 w / w%, about 27 w / w%, about 28 w / w%, about 29 w / w%, or about 30 w / w% of the sodium salt of the compound of Formula la or lb. In some embodiments, the tablet comprises about 20 w / w% to about 21 w / w% of the sodium salt of the compound of Formula la or lb. In some embodiments, the tablet comprises about 20.2 w / w% to about 20.7 w / w% of the sodium salt of the compound of Formula la or lb. In some embodiments, the tablet comprises about 20.45 w / w% of the sodium salt of the compound of Formula la or lb. In some embodiments, the tablet comprises about 20.46 w / w% of the sodium salt of the compound of Formula la or lb.

[0138] 15 In some embodiments, the tablet comprises about 18 w / w% to about 30 w / w% of the compound of Formula la or lb free acid, for example, about 18 w / w%, about 19 w / w%, about 20 w / w%, about 21 w / w%, about 22 w / w%, about 23 w / w%, about 24 w / w%, about 25 w / w%, about 26 w / w%, about 27 w / w%, about 28 w / w%, about 29 w / w%, or about 30 w / w% of the compound of Formula la or lb free acid. In some

[0139] 20 embodiments, the tablet comprises about 19 w / w% to about 21 w / w% of the compound of Formula la or lb free acid. In some embodiments, the tablet comprises about 19.8 w / w% to about 20.2 w / w% of the compound of Formula la or lb free acid. In some embodiments, the tablet comprises about 20.0 w / w% of the compound of Formula la or lb free acid.

[0140] In some embodiments, the tablet comprises about 18 w / w% to about 30 w / w% of the compound of Formula la free acid, for example, about 18 w / w%, about 19 w / w%, about 20 w / w%, about 21 w / w%, about 22 w / w%, about 23 w / w%, about 24 w / w%, about 25 w / w%, about 26 w / w%, about 27 w / w%, about 28 w / w%, about 29 w / w%, or about 30 w / w% of the compound of Formula la free acid. In some

[0141] 30 embodiments, the tablet comprises about 19 w / w% to about 21 w / w% of the compound of Formula la free acid. In some embodiments, the tablet comprises about 19.80 w / w% to about 20.2 w / w% of the compound of Formula la free acid. In some PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0142] 1572-WO-PCT / 35648-0367WO1 PATENT embodiments, the tablet comprises about 20.0 w / w% of the compound of Formula la free acid.

[0143] In some embodiments, the tablet comprises about 18 w / w% to about 30 w / w% of the compound of Formula lb free acid, for example, about 18 w / w%, about 19

[0144] 5 w / w%, about 20 w / w%, about 21 w / w%, about 22 w / w%, about 23 w / w%, about 24 w / w%, about 25 w / w%, about 26 w / w%, about 27 w / w%, about 28 w / w%, about 29 w / w%, or about 30 w / w% of the compound of Formula lb free acid. In some embodiments, the tablet comprises about 19 w / w% to about 21 w / w% of the compound of Formula lb free acid. In some embodiments, the tablet comprises about 19.8 w / w% to about 20.2 w / w% of the compound of Formula lb free acid. In some embodiments, the tablet comprises about 20.0 w / w% of the compound of Formula lb free acid.

[0145] In some embodiments, the tablet comprises about 0.01 w / w% to about 2.0 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt,

[0146] 15 co-crystal, solvate, or combination thereof, for example, about 0.01 w / w%, about 0.02 w / w%, about 0.03 w / w%, about 0.04 w / w%, about 0.05 w / w%, about 0.06 w / w%, about 0.07 w / w%, about 0.08 w / w%, about 0.09 w / w%, about 0.10 w / w%, about 0.30 w / w%, about 0.40 w / w%, about 0.50 w / w%, about 0.60 w / w%, about 0.70 w / w%, about 0.80 w / w%, about 0.90 w / w%, about 1.0 w / w%, about 1.1 w / w%, about 1.2

[0147] 20 w / w%, about 1.3 w / w%, about 1.4 w / w%, about 1.5 w / w%, about 1.6 w / w%, about 1.7 w / w%, about 1.8 w / w%, about 1.9 w / w%, or about 2.0 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[0148] In some embodiments, the tablet comprises about 0.02 w / w% to about 0.2 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[0149] In some embodiments, the tablet comprises about 0.03 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[0150] 30 In some embodiments, the tablet comprises about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof. In some embodiments, the tablet PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0151] 1572-WO-PCT / 35648-0367WO1 PATENT comprises about 0.14 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof. In some embodiments, the tablet comprises about 0.142 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination

[0152] 5 thereof.

[0153] In some embodiments, the tablet comprises about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof. In some embodiments, the tablet comprises about 0.035 w / w% to about 0.036 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof. In some embodiments, the tablet comprises about 0.0355 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[0154] In some embodiments, the tablet comprises about 0.01 w / w% to about 2.0

[0155] 15 w / w% of the compound of Formula Ila or lib, or a solvate thereof, for example, about 0.01 w / w%, about 0.02 w / w%, about 0.03 w / w%, about 0.04 w / w%, about 0.05 w / w%, about 0.06 w / w%, about 0.07 w / w%, about 0.08 w / w%, about 0.09 w / w%, about 0.10 w / w%, about 0.30 w / w%, about 0.40 w / w%, about 0.50 w / w%, about 0.60 w / w%, about 0.70 w / w%, about 0.80 w / w%, about 0.90 w / w%, about 1.0 w / w%,

[0156] 20 about 1.1 w / w%, about 1.2 w / w%, about 1.3 w / w%, about 1.4 w / w%, about 1.5 w / w%, about 1.6 w / w%, about 1.7 w / w%, about 1.8 w / w%, about 1.9 w / w%, or about 2.0 w / w% of the compound of Formula Ila or lib, or a solvate thereof.

[0157] In some embodiments, the tablet comprises about 0.02 w / w% to about 0.2 w / w% of the compound of Formula Ila or lib, or a solvate thereof. In some embodiments, the tablet comprises about 0.03 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a solvate thereof.

[0158] In some embodiments, the tablet comprises about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a solvate thereof. In some embodiments, the tablet comprises about 0.14 w / w% of the compound of Formula Ila

[0159] 30 or lib, or a solvate thereof. In some embodiments, the tablet comprises about 0.142 w / w% of the compound of Formula Ila or lib, or a solvate thereof. PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0160] 1572-WO-PCT / 35648-0367WO1 PATENT

[0161] In some embodiments, the tablet comprises about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof. In some embodiments, the tablet comprises about 0.035 w / w% to about 0.036 w / w% of the compound of Formula Ila or lib, or a solvate thereof. In some embodiments, the tablet

[0162] 5 comprises about 0.0355 w / w% of the compound of Formula Ila or lib, or a solvate thereof.

[0163] In some embodiments, the tablet comprises about 0.01 w / w% to about 2.0 w / w% of the monohydrate of the compound of Formula Ila or lib, for example, about 0.01 w / w%, about 0.02 w / w%, about 0.03 w / w%, about 0.04 w / w%, about 0.05 w / w%, about 0.06 w / w%, about 0.07 w / w%, about 0.08 w / w%, about 0.09 w / w%, about 0.10 w / w%, about 0.30 w / w%, about 0.40 w / w%, about 0.50 w / w%, about 0.60 w / w%, about 0.70 w / w%, about 0.80 w / w%, about 0.90 w / w%, about 1.0 w / w%, about 1.1 w / w%, about 1.2 w / w%, about 1.3 w / w%, about 1.4 w / w%, about 1.5 w / w%, about 1.6 w / w%, about 1.7 w / w%, about 1.8 w / w%, about 1.9 w / w%, or about

[0164] 15 2.0 w / w% of the monohydrate of the compound of Formula Ila or lib.

[0165] In some embodiments, the tablet comprises about 0.02 w / w% to about 0.2 w / w% of the monohydrate of the compound of Formula Ila or lib. In some embodiments, the tablet comprises about 0.03 w / w% to about 0.15 w / w% of the monohydrate of the compound of Formula Ila or lib.

[0166] 20 In some embodiments, the tablet comprises about 0.14 w / w% to about 0.15 w / w% of the monohydrate of the compound of Formula Ila or lib. In some embodiments, the tablet comprises about 0.14 w / w% of the monohydrate of the compound of Formula Ila or lib . In some embodiments, the tablet comprises about 0.142 w / w% of the monohydrate of the compound of Formula Ila or lib.

[0167] In some embodiments, the tablet comprises about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib. In some embodiments, the tablet comprises about 0.035 w / w% to about 0.036 w / w% of the monohydrate of the compound of Formula Ila or lib. In some embodiments, the tablet comprises about 0.0355 w / w% of the monohydrate of the compound of Formula Ila or

[0168] 30 lib.

[0169] In some embodiments, the tablet disclosed herein comprises a compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0170] 1572-WO-PCT / 35648-0367WO1 PATENT combination thereof, a compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, and one or more pharmaceutically acceptable excipients selected from the group consisting of a filler, a disintegrant, and a lubricant.

[0171] 5 In some embodiments, the one or more fillers comprise microcrystalline cellulose and / or mannitol. In some embodiments, the one or more fillers comprise microcrystalline cellulose and mannitol. In some embodiments, the disintegrant comprises croscarmellose sodium. In some embodiments, the lubricant comprises magnesium stearate.

[0172] In some embodiments, the tablet comprises one or more pharmaceutically acceptable excipients selected from mannitol, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate, or any combination thereof. In some embodiments, the tablet comprises mannitol, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate.

[0173] 15 In some embodiments, the tablet disclosed herein comprises a compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, a compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, mannitol, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate.

[0174] 20 In some embodiments, the tablet disclosed herein comprises a compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, a compound of Formula Ila or lib, or a solvate thereof, mannitol, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate.

[0175] In some embodiments, the tablet disclosed herein comprises a sodium salt of the Formula la or lb, or a pharmaceutically acceptable salt thereof, a monohydrate of the compound of Formula Ila or lib, mannitol, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate.

[0176] In some embodiments, the tablet comprises about 35 w / w% to about 45 w / w% of mannitol, for example, about 35 w / w%, about 36 w / w%, about 37 w / w%, about 38

[0177] 30 w / w%, about 39 w / w%, about 40 w / w%, about 41 w / w%, about 42 w / w%, about 43 w / w%, about 44 w / w%, or about 45 w / w% of mannitol. In some embodiments, the tablet comprises about 40 w / w% to about 42 w / w% of mannitol. In some PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0178] 1572-WO-PCT / 35648-0367WO1 PATENT embodiments, the tablet comprises about 41.3 w / w% to about 41.5 w / w% of mannitol. In some embodiments, the tablet comprises about 41.4 w / w% of mannitol.

[0179] In some embodiments, the tablet comprises about 20 w / w% to about 25 w / w% of microcrystalline cellulose, for example, about 20 w / w%, about 21 w / w%, about 22

[0180] 5 w / w%, about 23 w / w%, about 24 w / w%, or about 25 w / w% microcrystalline cellulose. In some embodiments, the tablet comprises about 22 w / w% to about 23 w / w% of microcrystalline cellulose. In some embodiments, the tablet comprises about 22.2 w / w% to about 22.4 w / w% of microcrystalline cellulose.

[0181] In some embodiments, the tablet comprises about 22.2 w / w% to about 22.3 w / w% microcrystalline cellulose. In some embodiments, the tablet comprises about 22.29 w / w% microcrystalline cellulose. In some embodiments, the tablet comprises about 22.288 w / w% microcrystalline cellulose.

[0182] In some embodiments, the tablet comprises about 22.3 w / w% to about 22.4 w / w% microcrystalline cellulose. In some embodiments, the tablet comprises about

[0183] 15 22.39 w / w% microcrystalline cellulose. In some embodiments, the tablet comprises about 22.3945 w / w% microcrystalline cellulose.

[0184] In some embodiments, the tablet comprises about 5 w / w% to about 10 w / w% of croscarmellose sodium, for example, about 5 w / w%, about 6 w / w%, about 7 w / w%, about 8 w / w%, about 9 w / w%, or about 10 w / w% croscarmellose sodium. In

[0185] 20 some embodiments, the tablet comprises about 7 w / w% to about 9 w / w% of croscarmellose sodium. In some embodiments, the tablet comprises about 7.5 w / w% to about 8.5 w / w% of croscarmellose sodium. In some embodiments, the tablet comprises about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium. In some embodiments, the tablet comprises about 8 w / w% of croscarmellose sodium.

[0186] In some embodiments, the tablet comprises about 0.1 w / w% to about 2.0 w / w% of magnesium stearate, for example, 0.1 w / w%, 0.2 w / w%, 0.3 w / w%, 0.4 w / w%, 0.5 w / w%, 0.6 w / w%, 0.7 w / w%, 0.8 w / w%, 0.9 w / w%, 1.0 w / w%, 1.1 w / w%, 1.2 w / w%, 1.3 w / w%, 1.4 w / w%, 1.5 w / w%, 1.6 w / w%, 1.7 w / w%, 1.8 w / w%, 1.9 w / w%, or about 2.0 w / w% magnesium stearate. In some embodiments, the

[0187] 30 tablet comprises about 1.0 w / w% to about 2.0 w / w% of magnesium stearate. In some embodiments, the tablet comprises about 1.4 w / w% to about 1.6 w / w% of magnesium PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0188] 1572-WO-PCT / 35648-0367WO1 PATENT stearate. In some embodiments, the tablet comprises about 1.5 w / w% of magnesium stearate.

[0189] In some embodiments, the tablet comprises: about 20 w / w% to about 30 w / w% of the compound of Formula la or lb, or a

[0190] 5 pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.01 w / w% to about 2.0 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[0191] In some embodiments, the tablet comprises: about 26 w / w% to about 27 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.02 w / w% to about 0.2 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and

[0192] 15 one or more pharmaceutically acceptable excipients.

[0193] In some embodiments, the tablet comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof;

[0194] 20 about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[0195] In some embodiments, the tablet comprises: about 26.67 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.142 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[0196] 30 In some embodiments, the tablet comprises: PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0197] 1572-WO-PCT / 35648-0367WO1 PATENT about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib,

[0198] 5 or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[0199] In some embodiments, the tablet comprises: about 26.67 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.0355 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[0200] In some embodiments, the tablet comprises:

[0201] 15 about 26 w / w% to about 27 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.02 w / w% to about 0.2 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[0202] 20 In some embodiments, the tablet comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[0203] In some embodiments, the tablet comprises: about 26.67 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.142 w / w% of the compound of Formula Ila or lib, or a

[0204] 30 pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[0205] In some embodiments, the tablet comprises: PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0206] 1572-WO-PCT / 35648-0367WO1 PATENT about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and

[0207] 5 one or more pharmaceutically acceptable excipients.

[0208] In some embodiments, the tablet comprises: about 26.67 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.0355 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[0209] In some embodiments, the tablet comprises: about 26 w / w% to about 27 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la or lb;

[0210] 15 about 0.02 w / w% to about 0.2 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[0211] In some embodiments, the tablet comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the

[0212] 20 sodium salt of the compound of Formula la or lb; about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[0213] In some embodiments, the tablet comprises: about 26.67 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la or lb; about 0.142 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[0214] 30 In some embodiments, the tablet comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la or lb; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0215] 1572-WO-PCT / 35648-0367WO1 PATENT about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[0216] In some embodiments, the tablet comprises:

[0217] 5 about 26.67 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la or lb; about 0.0355 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[0218] In some embodiments, the tablet comprises: about 26 w / w% to about 27 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la; about 0.02 w / w% to about 0.2 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and

[0219] 15 one or more pharmaceutically acceptable excipients.

[0220] In some embodiments, the tablet comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la; about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib,

[0221] 20 or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[0222] In some embodiments, the tablet comprises: about 26.67 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la; about 0.142 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[0223] In some embodiments, the tablet comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the

[0224] 30 sodium salt of the compound of Formula la; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0225] 1572-WO-PCT / 35648-0367WO1 PATENT one or more pharmaceutically acceptable excipients.

[0226] In some embodiments, the tablet comprises: about 26.67 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la;

[0227] 5 about 0.0355 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[0228] In some embodiments, the tablet comprises: about 26 w / w% to about 27 w / w% of the lenacapavir spray dried dispersion; about 0.02 w / w% to about 0.2 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[0229] In some embodiments, the tablet comprises: about 26.6 w / w% to about 26.7 w / w% of the lenacapavir spray dried

[0230] 15 dispersion; about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[0231] In some embodiments, the tablet comprises:

[0232] 20 about 26.67 w / w% of the lenacapavir spray dried dispersion; about 0.142 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[0233] In some embodiments, the tablet comprises: about 26.6 w / w% to about 26.7 w / w% of the lenacapavir spray dried dispersion; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[0234] 30 In some embodiments, the tablet comprises: about 26.67 w / w% of the lenacapavir spray dried dispersion; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0235] 1572-WO-PCT / 35648-0367WO1 PATENT about 0.0355 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[0236] In some embodiments, the tablet comprises:

[0237] 5 about 18 w / w% to about 30 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.01 w / w% to about 2.0 w / w% of the compound of Formula Ila or lib, or a solvate thereof; and one or more pharmaceutically acceptable excipients.

[0238] In some embodiments, the tablet comprises: about 19 w / w% to about 21 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.02 w / w% to about 0.2 w / w% of the compound of Formula Ila or lib, or a solvate thereof; and

[0239] 15 one or more pharmaceutically acceptable excipients.

[0240] In some embodiments, the tablet comprises: about 19.8 w / w% to about 20.8 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib,

[0241] 20 or a solvate thereof; and one or more pharmaceutically acceptable excipients.

[0242] In some embodiments, the tablet comprises: about 20.46 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.142 w / w% of the compound of Formula Ila or lib, or a solvate thereof; and one or more pharmaceutically acceptable excipients.

[0243] In some embodiments, the tablet comprises: about 20.45 w / w% of the compound of Formula la or lb, or a

[0244] 30 pharmaceutically acceptable salt thereof; about 0.142 w / w% of the compound of Formula Ila or lib, or a solvate thereof; and PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0245] 1572-WO-PCT / 35648-0367WO1 PATENT one or more pharmaceutically acceptable excipients.

[0246] In some embodiments, the tablet comprises: about 20.0 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof;

[0247] 5 about 0.142 w / w% of the compound of Formula Ila or lib, or a solvate thereof; and one or more pharmaceutically acceptable excipients.

[0248] In some embodiments, the tablet comprises: about 19 w / w% to about 21 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof; and one or more pharmaceutically acceptable excipients.

[0249] In some embodiments, the tablet comprises:

[0250] 15 about 19.8 w / w% to about 20.8 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof; and one or more pharmaceutically acceptable excipients.

[0251] 20 In some embodiments, the tablet comprises: about 20.46 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.0355 w / w% of the compound of Formula Ila or lib, or a solvate thereof; and one or more pharmaceutically acceptable excipients.

[0252] In some embodiments, the tablet comprises: about 20.45 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.0355 w / w% of the compound of Formula Ila or lib, or a solvate

[0253] 30 thereof; and one or more pharmaceutically acceptable excipients.

[0254] In some embodiments, the tablet comprises: PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0255] 1572-WO-PCT / 35648-0367WO1 PATENT about 20.0 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.0355 w / w% of the compound of Formula Ila or lib, or a solvate thereof; and

[0256] 5 one or more pharmaceutically acceptable excipients.

[0257] In some embodiments, the tablet comprises: about 18 w / w% to about 30 w / w% of the sodium salt of the compound of Formula la or lb; about 0.01 w / w% to about 2.0 w / w% of the monohydrate of the compound of Formula Ila or lib; and one or more pharmaceutically acceptable excipients.

[0258] In some embodiments, the tablet comprises: about 20 w / w% to about 21 w / w% of the sodium salt of the compound of Formula la or lb;

[0259] 15 about 0.02 w / w% to about 0.2 w / w% of the monohydrate of the compound of Formula Ila or lib; and one or more pharmaceutically acceptable excipients.

[0260] In some embodiments, the tablet comprises: about 20.2 w / w% to about 20.7 w / w% of the sodium salt of the compound of

[0261] 20 Formula la or lb; about 0.14 w / w% to about 0.15 w / w% of the monohydrate of the compound of Formula Ila or lib; and one or more pharmaceutically acceptable excipients.

[0262] In some embodiments, the tablet comprises: about 20.46 w / w% of the sodium salt of the compound of Formula la or lb; about 0.142 w / w% of the monohydrate of the compound of Formula Ila or lib; and one or more pharmaceutically acceptable excipients.

[0263] In some embodiments, the tablet comprises:

[0264] 30 about 20.45 w / w% of the sodium salt of the compound of Formula la or lb; about 0.142 w / w% of the monohydrate of the compound of Formula Ila or lib; and PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0265] 1572-WO-PCT / 35648-0367WO1 PATENT one or more pharmaceutically acceptable excipients.

[0266] In some embodiments, the tablet comprises: about 20.2 w / w% to about 20.7 w / w% of the sodium salt of the compound of Formula la or lb;

[0267] 5 about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib; and one or more pharmaceutically acceptable excipients.

[0268] In some embodiments, the tablet comprises: about 20.46 w / w% of the sodium salt of the compound of Formula la or lb; about 0.0355 w / w% of the monohydrate of the compound of Formula Ila or lib; and one or more pharmaceutically acceptable excipients.

[0269] In some embodiments, the tablet comprises: about 20.45 w / w% of the sodium salt of the compound of Formula la or lb;

[0270] 15 about 0.0355 w / w% of the monohydrate of the compound of Formula Ila or lib; and one or more pharmaceutically acceptable excipients.

[0271] In some embodiments, the tablet comprises: about 35 w / w% to about 45 w / w% of mannitol;

[0272] 20 about 20 w / w% to about 25 w / w% of microcrystalline cellulose; about 5 w / w% to about 10 w / w% of croscarmellose sodium; and about 0.1 w / w% to about 2.0 w / w% of magnesium stearate.

[0273] In some embodiments, the tablet comprises: about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; and about 1.0 w / w% to about 2.0 w / w% of magnesium stearate

[0274] In some embodiments, the tablet comprises: about 41 w / w% to about 42 w / w% of mannitol;

[0275] 30 about 22.2 w / w% to about 22.3 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate. PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0276] 1572-WO-PCT / 35648-0367WO1 PATENT

[0277] In some embodiments, the tablet comprises: about 41.40 w / w% of mannitol; about 22.288 w / w% microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and

[0278] 5 about 1.5 w / w% of magnesium stearate.

[0279] In some embodiments, the tablet comprises: about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0280] In some embodiments, the tablet comprises: about 41.40 w / w% of mannitol; about 22.3945 w / w% microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and

[0281] 15 about 1.5 w / w% of magnesium stearate.

[0282] In some embodiments, the tablet comprises: about 20 w / w% to about 30 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.01 w / w% to about 2.0 w / w% of the compound of Formula Ila or lib,

[0283] 20 or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 35 w / w% to about 45 w / w% of mannitol; about 20 w / w% to about 25 w / w% of microcrystalline cellulose; about 5 w / w% to about 10 w / w% of croscarmellose sodium; and about 0.1 w / w% to about 2.0 w / w% of magnesium stearate.

[0284] In some embodiments, the tablet comprises: about 26 w / w% to about 27 w / w% of the lenacapavir spray dried dispersion; about 0.02 w / w% to about 0.2 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 40 w / w% to about 42 w / w% of mannitol;

[0285] 30 about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; and about 1.0 w / w% to about 2.0 w / w% of magnesium stearate. PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0286] 1572-WO-PCT / 35648-0367WO1 PATENT

[0287] In some embodiments, the tablet comprises: about 26.6 w / w% to about 26.7 w / w% of the lenacapavir spray dried dispersion; about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib,

[0288] 5 or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41 w / w% to about 42 w / w% of mannitol; about 22.2 w / w% to about 22.3 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0289] In some embodiments, the tablet comprises: about 26.67 w / w% of the lenacapavir spray dried dispersion; about 0.142 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.40 w / w% of mannitol;

[0290] 15 about 22.288 w / w% microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[0291] In some embodiments, the tablet comprises: about 26.6 w / w% to about 26.7 w / w% of the lenacapavir spray dried

[0292] 20 dispersion; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0293] In some embodiments, the tablet comprises: about 26.67 w / w% of the lenacapavir spray dried dispersion; about 0.0355 w / w% of the compound of Formula Ila or lib, or a

[0294] 30 pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.40 w / w% of mannitol; about 22.3945 w / w% microcrystalline cellulose; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0295] 1572-WO-PCT / 35648-0367WO1 PATENT about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[0296] In some embodiments, the tablet comprises: about 26 w / w% to about 27 w / w% of the spray dried dispersion of the

[0297] 5 compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.02 w / w% to about 0.2 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; and about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[0298] In some embodiments, the tablet comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the

[0299] 15 compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41 w / w% to about 42 w / w% of mannitol;

[0300] 20 about 22.2 w / w% to about 22.3 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0301] In some embodiments, the tablet comprises: about 26.67 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.142 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.40 w / w% of mannitol;

[0302] 30 about 22.288 w / w% microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate. PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0303] 1572-WO-PCT / 35648-0367WO1 PATENT

[0304] In some embodiments, the tablet comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof;

[0305] 5 about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0306] In some embodiments, the tablet comprises: about 26.67 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof;

[0307] 15 about 0.0355 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.40 w / w% of mannitol; about 22.3945 w / w% microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and

[0308] 20 about 1.5 w / w% of magnesium stearate.

[0309] In some embodiments, the tablet comprises: about 26 w / w% to about 27 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.02 w / w% to about 0.2 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; and about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[0310] 30 In some embodiments, the tablet comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0311] 1572-WO-PCT / 35648-0367WO1 PATENT about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41 w / w% to about 42 w / w% of mannitol; about 22.2 w / w% to about 22.3 w / w% of microcrystalline cellulose;

[0312] 5 about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0313] In some embodiments, the tablet comprises: about 26.67 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.142 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.40 w / w% of mannitol; about 22.288 w / w% microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and

[0314] 15 about 1.5 w / w% of magnesium stearate.

[0315] In some embodiments, the tablet comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib,

[0316] 20 or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0317] In some embodiments, the tablet comprises: about 26.67 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.0355 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof;

[0318] 30 about 41.40 w / w% of mannitol; about 22.3945 w / w% microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0319] 1572-WO-PCT / 35648-0367WO1 PATENT about 1.5 w / w% of magnesium stearate.

[0320] In some embodiments, the tablet comprises: about 26 w / w% to about 27 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la or lb;

[0321] 5 about 0.02 w / w% to about 0.2 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; and about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[0322] In some embodiments, the tablet comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la or lb; about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib,

[0323] 15 or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41 w / w% to about 42 w / w% of mannitol; about 22.2 w / w% to about 22.3 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0324] 20 In some embodiments, the tablet comprises: about 26.67 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la or lb; about 0.142 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.40 w / w% of mannitol; about 22.288 w / w% microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[0325] In some embodiments, the tablet comprises:

[0326] 30 about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la or lb; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0327] 1572-WO-PCT / 35648-0367WO1 PATENT about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose;

[0328] 5 about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0329] In some embodiments, the tablet comprises: about 26.67 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la or lb; about 0.0355 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.40 w / w% of mannitol; about 22.3945 w / w% microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and

[0330] 15 about 1.5 w / w% of magnesium stearate.

[0331] In some embodiments, the tablet comprises: about 26 w / w% to about 27 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la; about 0.02 w / w% to about 0.2 w / w% of the compound of Formula Ila or lib,

[0332] 20 or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; and about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[0333] In some embodiments, the tablet comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la; about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof;

[0334] 30 about 41 w / w% to about 42 w / w% of mannitol; about 22.2 w / w% to about 22.3 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0335] 1572-WO-PCT / 35648-0367WO1 PATENT about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0336] In some embodiments, the tablet comprises: about 26.67 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la;

[0337] 5 about 0.142 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.40 w / w% of mannitol; about 22.288 w / w% microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[0338] In some embodiments, the tablet comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib,

[0339] 15 or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0340] 20 In some embodiments, the tablet comprises: about 26.67 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la; about 0.0355 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.40 w / w% of mannitol; about 22.3945 w / w% microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[0341] In some embodiments, the tablet comprises:

[0342] 30 about 19 w / w% to about 21 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0343] 1572-WO-PCT / 35648-0367WO1 PATENT about 0.02 w / w% to about 0.2 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose;

[0344] 5 about 7 w / w% to about 9 w / w% of croscarmellose sodium; and about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[0345] In some embodiments, the tablet comprises: about 19.8 w / w% to about 20.8 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41 w / w% to about 42 w / w% of mannitol; about 22.2 w / w% to about 22.3 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and

[0346] 15 about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0347] In some embodiments, the tablet comprises: about 20.45 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.142 w / w% of the compound of Formula Ila or lib, or a

[0348] 20 pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.40 w / w% of mannitol; about 22.288 w / w% microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[0349] In some embodiments, the tablet comprises: about 19.8 w / w% to about 20.8 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof;

[0350] 30 about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0351] 1572-WO-PCT / 35648-0367WO1 PATENT about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0352] In some embodiments, the tablet comprises: about 20.45 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof;

[0353] 5 about 0.0355 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.40 w / w% of mannitol; about 22.3945 w / w% microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[0354] In some embodiments, the tablet comprises: about 20 w / w% to about 21 w / w% of the sodium salt of the compound of Formula la or lb; about 0.02 w / w% to about 0.2 w / w% of the compound of Formula Ila or lib,

[0355] 15 or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; and about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[0356] 20 In some embodiments, the tablet comprises: about 20.2 w / w% to about 20.7 w / w% of the sodium salt of the compound of Formula la or lb; about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41 w / w% to about 42 w / w% of mannitol; about 22.2 w / w% to about 22.3 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0357] In some embodiments, the tablet comprises:

[0358] 30 about 20.45 w / w% of the sodium salt of the compound of Formula la or lb; about 0.142 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0359] 1572-WO-PCT / 35648-0367WO1 PATENT about 41.40 w / w% of mannitol; about 22.288 w / w% microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[0360] 5 In some embodiments, the tablet comprises: about 20.2 w / w% to about 20.7 w / w% of the sodium salt of the compound of Formula la or lb; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0361] In some embodiments, the tablet comprises:

[0362] 15 about 20.45 w / w% of the sodium salt of the compound of Formula la or lb; about 0.0355 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.40 w / w% of mannitol; about 22.3945 w / w% microcrystalline cellulose;

[0363] 20 about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[0364] In some embodiments, the tablet comprises: about 19 w / w% to about 21 w / w% of the compound of Formula la or lb free acid; about 0.02 w / w% to about 0.2 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; and

[0365] 30 about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[0366] In some embodiments, the tablet comprises: PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0367] 1572-WO-PCT / 35648-0367WO1 PATENT about 19.8 w / w% to about 20.2 w / w% of the compound of Formula la or lb free acid; about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof;

[0368] 5 about 41 w / w% to about 42 w / w% of mannitol; about 22.2 w / w% to about 22.3 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0369] In some embodiments, the tablet comprises: about 20.0 w / w% of the compound of Formula la or lb free acid; about 0.142 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.40 w / w% of mannitol; about 22.288 w / w% microcrystalline cellulose;

[0370] 15 about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[0371] In some embodiments, the tablet comprises: about 19.8 w / w% to about 20.2 w / w% of the compound of Formula la or lb free acid;

[0372] 20 about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0373] In some embodiments, the tablet comprises: about 20.0 w / w% of the compound of Formula la or lb free acid; about 0.0355 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof;

[0374] 30 about 41.40 w / w% of mannitol; about 22.3945 w / w% microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0375] 1572-WO-PCT / 35648-0367WO1 PATENT about 1.5 w / w% of magnesium stearate.

[0376] In some embodiments, the tablet comprises: about 19 w / w% to about 21 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof;

[0377] 5 about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; and about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[0378] In some embodiments, the tablet comprises: about 19.8 w / w% to about 20.8 w / w% of the compound of Formula la or lb, or

[0379] 15 a pharmaceutically acceptable salt thereof; about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407;

[0380] 20 about 41 w / w% to about 42 w / w% of mannitol; about 22.2 w / w% to about 22.3 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0381] In some embodiments, the tablet comprises: about 20.46 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.142 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4.88 w / w% of copovidone; about 1.33 w / w% of poloxamer 407;

[0382] 30 about 41.40 w / w% of mannitol; about 22.288 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0383] 1572-WO-PCT / 35648-0367WO1 PATENT about 1.5 w / w% of magnesium stearate.

[0384] In some embodiments, the tablet comprises: about 19 w / w% to about 21 w / w% of the sodium salt of the compound of Formula la or lb;

[0385] 5 about 0.14 w / w% to about 0.15 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; and about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[0386] In some embodiments, the tablet comprises: about 19.8 w / w% to about 20.8 w / w% of the sodium salt of the compound of

[0387] 15 Formula la or lb; about 0.14 w / w% to about 0.15 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407;

[0388] 20 about 41 w / w% to about 42 w / w% of mannitol; about 22.2 w / w% to about 22.3 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0389] In some embodiments, the tablet comprises: about 20.46 w / w% of the sodium salt of the compound of Formula la or lb; about 0.142 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4.88 w / w% of copovidone; about 1.33 w / w% of poloxamer 407; about 41.40 w / w% of mannitol;

[0390] 30 about 22.288 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate. PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0391] 1572-WO-PCT / 35648-0367WO1 PATENT

[0392] In some embodiments, the tablet comprises: about 19 w / w% to about 21 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib,

[0393] 5 or a solvate thereof; about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; about 1.0 w / w% to about 2.0 w / w% of magnesium stearate; and an outer film coat.

[0394] In some embodiments, the tablet comprises: about 19.8 w / w% to about 20.8 w / w% of the compound of Formula la or lb, or

[0395] 15 a pharmaceutically acceptable salt thereof; about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407;

[0396] 20 about 41 w / w% to about 42 w / w% of mannitol; about 22.2 w / w% to about 22.3 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; about 1.4 w / w% to about 1.6 w / w% of magnesium stearate; and an outer film coat.

[0397] In some embodiments, the tablet comprises: about 20.46 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.142 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4.88 w / w% of copovidone;

[0398] 30 about 1.33 w / w% of poloxamer 407; about 41.40 w / w% of mannitol; about 22.288 w / w% of microcrystalline cellulose; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0399] 1572-WO-PCT / 35648-0367WO1 PATENT about 8.0 w / w% of croscarmellose sodium; about 1.5 w / w% of magnesium stearate; and an outer film coat.

[0400] In some embodiments, the tablet comprises:

[0401] 5 about 19 w / w% to about 21 w / w% of the sodium salt of the compound of Formula la or lb; about 0.14 w / w% to about 0.15 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; about 1.0 w / w% to about 2.0 w / w% of magnesium stearate; and

[0402] 15 an outer film coat.

[0403] In some embodiments, the tablet comprises: about 19.8 w / w% to about 20.8 w / w% of the sodium salt of the compound of Formula la or lb; about 0.14 w / w% to about 0.15 w / w% of the monohydrate of the compound of

[0404] 20 Formula Ila or lib; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.2 w / w% to about 22.3 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; about 1.4 w / w% to about 1.6 w / w% of magnesium stearate; and an outer film coat.

[0405] In some embodiments, the tablet comprises: about 20.46 w / w% of the sodium salt of the compound of Formula la or lb;

[0406] 30 about 0.142 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4.88 w / w% of copovidone; about 1.33 w / w% of poloxamer 407; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0407] 1572-WO-PCT / 35648-0367WO1 PATENT about 41.40 w / w% of mannitol; about 22.288 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; about 1.5 w / w% of magnesium stearate; and

[0408] 5 an outer film coat.

[0409] In some embodiments, the tablet consists essentially of: about 19 w / w% to about 21 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose;

[0410] 15 about 7 w / w% to about 9 w / w% of croscarmellose sodium; and about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[0411] In some embodiments, the tablet consists essentially of: about 19.8 w / w% to about 20.8 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof;

[0412] 20 about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.2 w / w% to about 22.3 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0413] In some embodiments, the tablet consists essentially of: about 20.46 w / w% of the compound of Formula la or lb, or a

[0414] 30 pharmaceutically acceptable salt thereof; about 0.142 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4.88 w / w% of copovidone; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0415] 1572-WO-PCT / 35648-0367WO1 PATENT about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.288 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and

[0416] 5 about 1.5 w / w% of magnesium stearate.

[0417] In some embodiments, the tablet consists essentially of: about 19 w / w% to about 21 w / w% of the sodium salt of the compound of Formula la or lb; about 0.14 w / w% to about 0.15 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose;

[0418] 15 about 7 w / w% to about 9 w / w% of croscarmellose sodium; and about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[0419] In some embodiments, the tablet consists essentially of: about 19.8 w / w% to about 20.8 w / w% of the sodium salt of the compound of Formula la or lb;

[0420] 20 about 0.14 w / w% to about 0.15 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.2 w / w% to about 22.3 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0421] In some embodiments, the tablet consists essentially of: about 20.46 w / w% of the sodium salt of the compound of Formula la or lb;

[0422] 30 about 0.142 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4.88 w / w% of copovidone; about 1.33 w / w% of poloxamer 407; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0423] 1572-WO-PCT / 35648-0367WO1 PATENT about 41.40 w / w% of mannitol; about 22.288 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[0424] 5 In some embodiments, the tablet consists essentially of: about 19 w / w% to about 21 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium;

[0425] 15 about 1.0 w / w% to about 2.0 w / w% of magnesium stearate; and an outer film coat.

[0426] In some embodiments, the tablet consists essentially of: about 19.8 w / w% to about 20.8 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof;

[0427] 20 about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.2 w / w% to about 22.3 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; about 1.4 w / w% to about 1.6 w / w% of magnesium stearate; and an outer film coat.

[0428] In some embodiments, the tablet consists essentially of:

[0429] 30 about 20.46 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.142 w / w% of the compound of Formula Ila or lib, or a solvate thereof; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0430] 1572-WO-PCT / 35648-0367WO1 PATENT about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.288 w / w% of microcrystalline cellulose;

[0431] 5 about 8.0 w / w% of croscarmellose sodium; about 1.5 w / w% of magnesium stearate; and an outer film coat.

[0432] In some embodiments, the tablet consists essentially of: about 19 w / w% to about 21 w / w% of the sodium salt of the compound of Formula la or lb; about 0.14 w / w% to about 0.15 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407;

[0433] 15 about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; about 1.0 w / w% to about 2.0 w / w% of magnesium stearate; and an outer film coat.

[0434] 20 In some embodiments, the tablet consists essentially of: about 19.8 w / w% to about 20.8 w / w% of the sodium salt of the compound of Formula la or lb; about 0.14 w / w% to about 0.15 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.2 w / w% to about 22.3 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium;

[0435] 30 about 1.4 w / w% to about 1.6 w / w% of magnesium stearate; and an outer film coat.

[0436] In some embodiments, the tablet consists essentially of: PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0437] 1572-WO-PCT / 35648-0367WO1 PATENT about 20.46 w / w% of the sodium salt of the compound of Formula la or lb; about 0.142 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407;

[0438] 5 about 41.40 w / w% of mannitol; about 22.288 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; about 1.5 w / w% of magnesium stearate; and an outer film coat.

[0439] In some embodiments, the tablet consists of: about 19 w / w% to about 21 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a solvate thereof;

[0440] 15 about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; and

[0441] 20 about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[0442] In some embodiments, the tablet consists of: about 19.8 w / w% to about 20.8 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.2 w / w% to about 22.3 w / w% of microcrystalline cellulose;

[0443] 30 about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0444] In some embodiments, the tablet consists of: PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0445] 1572-WO-PCT / 35648-0367WO1 PATENT about 20.46 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.142 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4.88 w / w% of copovidone;

[0446] 5 about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.288 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[0447] In some embodiments, the tablet consists of: about 19 w / w% to about 21 w / w% of the sodium salt of the compound of Formula la or lb; about 0.14 w / w% to about 0.15 w / w% of the monohydrate of the compound of Formula Ila or lib;

[0448] 15 about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; and

[0449] 20 about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[0450] In some embodiments, the tablet consists of: about 19.8 w / w% to about 20.8 w / w% of the sodium salt of the compound of Formula la or lb; about 0.14 w / w% to about 0.15 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.2 w / w% to about 22.3 w / w% of microcrystalline cellulose;

[0451] 30 about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0452] In some embodiments, the tablet consists of: PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0453] 1572-WO-PCT / 35648-0367WO1 PATENT about 20.46 w / w% of the sodium salt of the compound of Formula la or lb; about 0.142 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407;

[0454] 5 about 41.40 w / w% of mannitol; about 22.288 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[0455] In some embodiments, the tablet consists of: about 19 w / w% to about 21 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 6 w / w% of copovidone;

[0456] 15 about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; about 1.0 w / w% to about 2.0 w / w% of magnesium stearate; and

[0457] 20 an outer film coat.

[0458] In some embodiments, the tablet consists of: about 19.8 w / w% to about 20.8 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.2 w / w% to about 22.3 w / w% of microcrystalline cellulose;

[0459] 30 about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; about 1.4 w / w% to about 1.6 w / w% of magnesium stearate; and an outer film coat. PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0460] 1572-WO-PCT / 35648-0367WO1 PATENT

[0461] In some embodiments, the tablet consists of: about 20.46 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.142 w / w% of the compound of Formula Ila or lib, or a solvate thereof;

[0462] 5 about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.288 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; about 1.5 w / w% of magnesium stearate; and an outer film coat.

[0463] In some embodiments, the tablet consists of: about 19 w / w% to about 21 w / w% of the sodium salt of the compound of Formula la or lb;

[0464] 15 about 0.14 w / w% to about 0.15 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol;

[0465] 20 about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; about 1.0 w / w% to about 2.0 w / w% of magnesium stearate; and an outer film coat.

[0466] In some embodiments, the tablet consists of: about 19.8 w / w% to about 20.8 w / w% of the sodium salt of the compound of Formula la or lb; about 0.14 w / w% to about 0.15 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 5 w / w% of copovidone;

[0467] 30 about 1 w / w% to about 2 w / w% of poloxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.2 w / w% to about 22.3 w / w% of microcrystalline cellulose; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0468] 1572-WO-PCT / 35648-0367WO1 PATENT about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; about 1.4 w / w% to about 1.6 w / w% of magnesium stearate; and an outer film coat.

[0469] In some embodiments, the tablet consists of:

[0470] 5 about 20.46 w / w% of the sodium salt of the compound of Formula la or lb; about 0.142 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.288 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; about 1.5 w / w% of magnesium stearate; and an outer film coat.

[0471] In some embodiments, the tablet comprises:

[0472] 15 about 19 w / w% to about 21 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 6 w / w% of copovidone;

[0473] 20 about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; and about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[0474] In some embodiments, the tablet comprises: about 19.8 w / w% to about 20.8 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof;

[0475] 30 about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407; about 41 w / w% to about 42 w / w% of mannitol; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0476] 1572-WO-PCT / 35648-0367WO1 PATENT about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0477] In some embodiments, the tablet comprises:

[0478] 5 about 20.46 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.0355 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.395 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[0479] 15 In some embodiments, the tablet comprises: about 19 w / w% to about 21 w / w% of the sodium salt of the compound of Formula la or lb; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib;

[0480] 20 about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; and about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[0481] In some embodiments, the tablet comprises: about 19.8 w / w% to about 20.8 w / w% of the sodium salt of the compound of Formula la or lb; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of

[0482] 30 Formula Ila or lib; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0483] 1572-WO-PCT / 35648-0367WO1 PATENT about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0484] 5 In some embodiments, the tablet comprises: about 20.46 w / w% of the sodium salt of the compound of Formula la or lb; about 0.0355 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.395 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[0485] 15 In some embodiments, the tablet comprises: about 19 w / w% to about 21 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof;

[0486] 20 about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; about 1.0 w / w% to about 2.0 w / w% of magnesium stearate; and an outer film coat.

[0487] In some embodiments, the tablet comprises: about 19.8 w / w% to about 20.8 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof;

[0488] 30 about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 5 w / w% of copovidone; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0489] 1572-WO-PCT / 35648-0367WO1 PATENT about 1 w / w% to about 2 w / w% of pol oxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium;

[0490] 5 about 1.4 w / w% to about 1.6 w / w% of magnesium stearate; and an outer film coat.

[0491] In some embodiments, the tablet comprises: about 20.46 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.0355 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol;

[0492] 15 about 22.395 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; about 1.5 w / w% of magnesium stearate; and an outer film coat.

[0493] In some embodiments, the tablet comprises:

[0494] 20 about 19 w / w% to about 21 w / w% of the sodium salt of the compound of Formula la or lb; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; about 1.0 w / w% to about 2.0 w / w% of magnesium stearate; and

[0495] 30 an outer film coat.

[0496] In some embodiments, the tablet comprises: PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0497] 1572-WO-PCT / 35648-0367WO1 PATENT about 19.8 w / w% to about 20.8 w / w% of the sodium salt of the compound of Formula la or lb; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib;

[0498] 5 about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of pol oxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; about 1.4 w / w% to about 1.6 w / w% of magnesium stearate; and an outer film coat.

[0499] In some embodiments, the tablet comprises: about 20.46 w / w% of the sodium salt of the compound of Formula la or lb; about 0.0355 w / w% of the monohydrate of the compound of Formula Ila or

[0500] 15 lib; about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.395 w / w% of microcrystalline cellulose;

[0501] 20 about 8.0 w / w% of croscarmellose sodium; about 1.5 w / w% of magnesium stearate; and an outer film coat.

[0502] In some embodiments, the tablet consists essentially of: about 19 w / w% to about 21 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407;

[0503] 30 about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; and PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0504] 1572-WO-PCT / 35648-0367WO1 PATENT about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[0505] In some embodiments, the tablet consists essentially of: about 19.8 w / w% to about 20.8 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof;

[0506] 5 about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of pol oxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0507] In some embodiments, the tablet consists essentially of: about 20.46 w / w% of the compound of Formula la or lb, or a

[0508] 15 pharmaceutically acceptable salt thereof; about 0.0355 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407;

[0509] 20 about 41.40 w / w% of mannitol; about 22.395 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[0510] In some embodiments, the tablet consists essentially of: about 19 w / w% to about 21 w / w% of the sodium salt of the compound of Formula la or lb; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 6 w / w% of copovidone;

[0511] 30 about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0512] 1572-WO-PCT / 35648-0367WO1 PATENT about 7 w / w% to about 9 w / w% of croscarmellose sodium; and about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[0513] In some embodiments, the tablet consists essentially of: about 19.8 w / w% to about 20.8 w / w% of the sodium salt of the compound of

[0514] 5 Formula la or lb; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of pol oxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0515] In some embodiments, the tablet consists essentially of:

[0516] 15 about 20.46 w / w% of the sodium salt of the compound of Formula la or lb; about 0.0355 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407;

[0517] 20 about 41.40 w / w% of mannitol; about 22.395 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[0518] In some embodiments, the tablet consists essentially of: about 19 w / w% to about 21 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 6 w / w% of copovidone;

[0519] 30 about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0520] 1572-WO-PCT / 35648-0367WO1 PATENT about 7 w / w% to about 9 w / w% of croscarmellose sodium; about 1.0 w / w% to about 2.0 w / w% of magnesium stearate; and an outer film coat.

[0521] In some embodiments, the tablet consists essentially of:

[0522] 5 about 19.8 w / w% to about 20.8 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of pol oxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; about 1.4 w / w% to about 1.6 w / w% of magnesium stearate; and

[0523] 15 an outer film coat.

[0524] In some embodiments, the tablet consists essentially of: about 20.46 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.0355 w / w% of the compound of Formula Ila or lib, or a solvate

[0525] 20 thereof; about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.395 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; about 1.5 w / w% of magnesium stearate; and an outer film coat.

[0526] In some embodiments, the tablet consists essentially of: about 19 w / w% to about 21 w / w% of the sodium salt of the compound of

[0527] 30 Formula la or lb; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0528] 1572-WO-PCT / 35648-0367WO1 PATENT about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose;

[0529] 5 about 7 w / w% to about 9 w / w% of croscarmellose sodium; about 1.0 w / w% to about 2.0 w / w% of magnesium stearate; and an outer film coat.

[0530] In some embodiments, the tablet consists essentially of: about 19.8 w / w% to about 20.8 w / w% of the sodium salt of the compound of Formula la or lb; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407;

[0531] 15 about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; about 1.4 w / w% to about 1.6 w / w% of magnesium stearate; and an outer film coat.

[0532] 20 In some embodiments, the tablet consists essentially of: about 20.46 w / w% of the sodium salt of the compound of Formula la or lb; about 0.0355 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4.88 w / w% of copovidone; about 1.33 w / w% of poloxamer 407; about 41.40 w / w% of mannitol; about 22.395 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; about 1.5 w / w% of magnesium stearate; and

[0533] 30 an outer film coat.

[0534] In some embodiments, the tablet consists of: PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0535] 1572-WO-PCT / 35648-0367WO1 PATENT about 19 w / w% to about 21 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof;

[0536] 5 about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; and about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[0537] In some embodiments, the tablet consists of: about 19.8 w / w% to about 20.8 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib,

[0538] 15 or a solvate thereof; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose;

[0539] 20 about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0540] In some embodiments, the tablet consists of: about 20.46 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.0355 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4.88 w / w% of copovidone; about 1.33 w / w% of poloxamer 407; about 41.40 w / w% of mannitol;

[0541] 30 about 22.395 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate. PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0542] 1572-WO-PCT / 35648-0367WO1 PATENT

[0543] In some embodiments, the tablet consists of: about 19 w / w% to about 21 w / w% of the sodium salt of the compound of Formula la or lb; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of

[0544] 5 Formula Ila or lib; about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; and about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[0545] In some embodiments, the tablet consists of: about 19.8 w / w% to about 20.8 w / w% of the sodium salt of the compound of Formula la or lb;

[0546] 15 about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407; about 41 w / w% to about 42 w / w% of mannitol;

[0547] 20 about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[0548] In some embodiments, the tablet consists of: about 20.46 w / w% of the sodium salt of the compound of Formula la or lb; about 0.0355 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4.88 w / w% of copovidone; about 1.33 w / w% of poloxamer 407; about 41.40 w / w% of mannitol;

[0549] 30 about 22.395 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate. PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0550] 1572-WO-PCT / 35648-0367WO1 PATENT

[0551] In some embodiments, the tablet consists of: about 19 w / w% to about 21 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib,

[0552] 5 or a solvate thereof; about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; about 1.0 w / w% to about 2.0 w / w% of magnesium stearate; and an outer film coat.

[0553] In some embodiments, the tablet consists of: about 19.8 w / w% to about 20.8 w / w% of the compound of Formula la or lb, or

[0554] 15 a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407;

[0555] 20 about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; about 1.4 w / w% to about 1.6 w / w% of magnesium stearate; and an outer film coat.

[0556] In some embodiments, the tablet consists of: about 20.46 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.0355 w / w% of the compound of Formula Ila or lib, or a solvate thereof;

[0557] 30 about 4.88 w / w% of copovidone; about 1.33 w / w% of poloxamer 407; about 41.40 w / w% of mannitol; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0558] 1572-WO-PCT / 35648-0367WO1 PATENT about 22.395 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; about 1.5 w / w% of magnesium stearate; and an outer film coat.

[0559] 5 In some embodiments, the tablet consists of: about 19 w / w% to about 21 w / w% of the sodium salt of the compound of Formula la or lb; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium;

[0560] 15 about 1.0 w / w% to about 2.0 w / w% of magnesium stearate; and an outer film coat.

[0561] In some embodiments, the tablet consists of: about 19.8 w / w% to about 20.8 w / w% of the sodium salt of the compound of Formula la or lb;

[0562] 20 about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; about 1.4 w / w% to about 1.6 w / w% of magnesium stearate; and an outer film coat.

[0563] In some embodiments, the tablet consists of:

[0564] 30 about 20.46 w / w% of the sodium salt of the compound of Formula la or lb; about 0.0355 w / w% of the monohydrate of the compound of Formula Ila or lib; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0565] 1572-WO-PCT / 35648-0367WO1 PATENT about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.395 w / w% of microcrystalline cellulose;

[0566] 5 about 8.0 w / w% of croscarmellose sodium; about 1.5 w / w% of magnesium stearate; and an outer film coat.

[0567] The tablets disclosed herein may be uncoated or coated (in which case they include an outer film coat). Although uncoated tablets may be used, it is more usual to provide a coated tablet, in which case a conventional non-enteric coating may be used. Film coatings are known in the art and can be composed of hydrophilic polymer materials, but are not limited to, polysaccharide materials, such as hydroxypropylmethyl cellulose (HPMC), methylcellulose, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), poly(vinylalcohol-co-ethylene glycol) and

[0568] 15 other water soluble polymers. Though the water-soluble material included in the film coating of the tablets may include a single polymer material, it may also be formed using a mixture of more than one polymer. The coating may be white or colored. Suitable coatings include, but are not limited to, polymeric film coatings such as those comprising polyvinyl alcohol e.g. Opadry® QX Grey, Opadry® QX Pink,

[0569] 20 Opadry® Clear, Opadry® TF Pink, and Opadry® TF Grey. The amount of coating will generally be between about 1-8% of the uncoated tablet’s weight.

[0570] In some embodiments, the tablet further comprises an outer film coat.

[0571] In some embodiments, the outer film coat is selected from the Opadry® QX Quick and Flexible Film Coating System 321 A series. In some embodiments, the outer film coat is selected from the Opadry® II Complete Film Coating System 85F series. In some embodiments, the outer film coat is selected from the Opadry® TF High Opacity PVA Film Coating 273F series. In some embodiments, the outer film coat is selected from the Opadry® TF Titanium Free Formulated Film Coating 266U series.

[0572] 30 In some embodiments, the outer film coat comprises Opadry® Clear.

[0573] In some embodiments, the outer film coat comprises Opadry® TF Pink.

[0574] In some embodiments, the outer film coat comprises Opadry® TF Grey. PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0575] 1572-WO-PCT / 35648-0367WO1 PATENT

[0576] In some embodiments, the outer film coat comprises about 0.5 w / w% to about

[0577] 1.5 w / w% Opadry® Clear, for example, about 0.5 w / w%, about 0.6 w / w%, about 0.7 w / w%, about 0.8 w / w%, about 0.9 w / w%, about 1.0 w / w%, about 1.1 w / w%, about 1.2 w / w%, about 1.3 w / w%, about 1.4 w / w%, or about 1.5 w / w% Opadry® Clear. In

[0578] 5 some embodiments, the outer film coat comprises about 0.9 w / w% to about 1.1 w / w% Opadry® Clear. In some embodiments, the outer film coat comprises about 1 w / w% Opadry® Clear.

[0579] In some embodiments, the outer film coat comprises Opadry® Clear and further comprises Opadry® TF Pink or Opadry® TF Gray.

[0580] In some embodiments, the outer film coat comprises Opadry® Clear and Opadry® TF Pink. In some embodiments, the outer film coat further comprises about

[0581] 3.5 w / w% to about 4.5 w / w% Opadry® TF Pink, for example, about 3.5 w / w%, about

[0582] 3.6 w / w%, about 3.7 w / w%, about 3.8 w / w%, about 3.9 w / w%, about 4.0 w / w%, about 4.1 w / w%, about 4.2 w / w%, about 4.3 w / w%, about 4.4 w / w%, or about 4.5

[0583] 15 w / w% Opadry® TF Pink. In some embodiments, the outer film coat comprises about 3.9 w / w% to about 4.1 w / w% Opadry® TF Pink. In some embodiments, the outer film coat comprises about 4 w / w% Opadry® TF Pink. In some embodiments, the outer film coat comprises about 1 w / w% Opadry® Clear and about 4 w / w% Opadry® TF Pink. In some embodiments, the outer film coat comprises about 0.9 w / w% to

[0584] 20 about 1.1 w / w% Opadry® Clear and about 3.9 w / w% to about 4.1 w / w% Opadry® TF Pink.

[0585] In some embodiments, the outer film coat comprises Opadry® Clear and Opadry® TF Gray. In some embodiments, the outer film coat comprises about 3.5 w / w% to about 4.5 w / w% Opadry® TF Gray, for example, about 3.5 w / w%, about 3.6 w / w%, about 3.7 w / w%, about 3.8 w / w%, about 3.9 w / w%, about 4.0 w / w%, about 4.1 w / w%, about 4.2 w / w%, about 4.3 w / w%, about 4.4 w / w%, or about 4.5 w / w% Opadry® TF Gray. In some embodiments, the outer film coat comprises about 3.9 w / w% to about 4.1 w / w% Opadry® TF Gray. In some embodiments, the outer film coat comprises about 4 w / w% Opadry® TF Gray. In some embodiments, the outer

[0586] 30 film coat comprises about 1 w / w% Opadry® Clear and about 4 w / w% Opadry® TF Gray. In some embodiments, the outer film coat comprises about 0.9 w / w% to about PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0587] 1572-WO-PCT / 35648-0367WO1 PATENT

[0588] 1.1 w / w% Opadry® Clear and about 3.9 w / w% to about 4.1 w / w% Opadry® TF Gray.

[0589] In some embodiments, the tablet comprises about 100 mg to about 500 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal,

[0590] 5 solvate, or combination thereof, for example, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, about 200 mg, 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg,

[0591] 15 about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg, about 405 mg, about 410 mg, about 415 mg, about 420 mg, about 425 mg, about 430 mg, about 435 mg, about 440 mg, about 445 mg, about 450 mg, about 455 mg, about 460 mg, about 465 mg, about 470 mg, about 475 mg, about 480 mg, about 485 mg, about 490 mg, about 495 mg, or about 500 mg of the compound of

[0592] 20 Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[0593] In some embodiments, the tablet comprises about 200 mg to about 500 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof. In some embodiments, the tablet comprises about 250 mg to about 450 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[0594] In some embodiments, the tablet comprises about 375 mg to about 425 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof. In some embodiments, the tablet comprises about 390

[0595] 30 mg to about 410 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof. In some embodiments, the tablet comprises about 399 mg to about 401 mg of the compound of Formula la or lb, PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0596] 1572-WO-PCT / 35648-0367WO1 PATENT or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof. In some embodiments, the tablet comprises about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[0597] 5 In some embodiments, the tablet comprises about 300 mg to about 500 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof. In some embodiments, the tablet comprises about 350 mg to about 450 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof. In some embodiments, the tablet comprises about 375 mg to about 425 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof. In some embodiments, the tablet comprises about 390 mg to about 410 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof. In some embodiments, the tablet comprises about 399 mg to about 401 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof. In some embodiments, the tablet comprises

[0598] 15 about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof.

[0599] In some embodiments, the tablet comprises about 300 mg to about 500 mg of the sodium salt of the compound of Formula la or lb. In some embodiments, the tablet comprises about 350 mg to about 450 mg of the sodium salt of the compound of

[0600] 20 Formula la or lb. In some embodiments, the tablet comprises about 375 mg to about 425 mg of the sodium salt of the compound of Formula la or lb. In some embodiments, the tablet comprises about 390 mg to about 410 mg of the sodium salt of the compound of Formula la or lb. In some embodiments, the tablet comprises about 399 mg to about 401 mg of the sodium salt of the compound of Formula la or lb. In some embodiments, the tablet comprises about 400 mg of the sodium salt of the compound of Formula la or lb.

[0601] In some embodiments, the tablet comprises about 200 mg to about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis. In some embodiments, the tablet

[0602] 30 comprises about 250 mg to about 450 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis. PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0603] 1572-WO-PCT / 35648-0367WO1 PATENT

[0604] In some embodiments, the tablet comprises about 275 mg to about 325 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis. In some embodiments, the tablet comprises about 290 mg to about 310 mg of the compound of Formula la or lb, or a

[0605] 5 pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis. In some embodiments, the tablet comprises about 299 mg to about 301 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, cocrystal, solvate, or combination thereof, on a free acid basis. In some embodiments, the tablet comprises about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis.

[0606] In some embodiments, the tablet comprises about 200 mg to about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis. In some embodiments, the tablet comprises about 250 mg to about 350

[0607] 15 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis. In some embodiments, the tablet comprises about 275 mg to about 325 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis. In some embodiments, the tablet comprises about 290 mg to about 310 mg of the compound of Formula la or lb, or a

[0608] 20 pharmaceutically acceptable salt thereof, on a free acid basis. In some embodiments, the tablet comprises about 299 mg to about 301 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis. In some embodiments, the tablet comprises about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis.

[0609] In some embodiments, the tablet comprises about 0.1 mg to about 25 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, for example, about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 2.0 mg, about 3.0 mg, about 4.0 mg, about 5 mg, about 6 mg,

[0610] 30 about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, or about 25 PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0611] 1572-WO-PCT / 35648-0367WO1 PATENT mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, cocrystal, solvate, or combination thereof.

[0612] In some embodiments, the tablet comprises about 0.4 mg to about 22 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal,

[0613] 5 solvate, or combination thereof. In some embodiments, the tablet comprises about 0.1 mg to about 2.5 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[0614] In some embodiments, the tablet comprises about 2.0 mg to about 2.2 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof. In some embodiments, the tablet comprises about 2.1 mg to about 2.2 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof. In some embodiments, the tablet comprises about 2.130 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof. In some

[0615] 15 embodiments, the tablet comprises about 2 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis.

[0616] In some embodiments, the tablet comprises about 0.4 mg to about 0.6 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal,

[0617] 20 solvate, or combination thereof. In some embodiments, the tablet comprises about 0.5 mg to about 0.6 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof. In some embodiments, the tablet comprises about 0.5325 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof. In some embodiments, the tablet comprises about 0.5 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis.

[0618] In some embodiments, the tablet comprises about 0.4 mg to about 22 mg of the compound of Formula Ila or lib, or a solvate thereof. In some embodiments, the

[0619] 30 tablet comprises about 0.1 mg to about 2.5 mg of the compound of Formula Ila or lib, or a solvate thereof. PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0620] 1572-WO-PCT / 35648-0367WO1 PATENT

[0621] In some embodiments, the tablet comprises about 2.0 mg to about 2.2 mg of the compound of Formula Ila or lib, or a solvate thereof. In some embodiments, the tablet comprises about 2.1 mg to about 2.2 mg of the compound of Formula Ila or lib, or a solvate thereof. In some embodiments, the tablet comprises about 2.130 mg of the

[0622] 5 compound of Formula Ila or lib, or a solvate thereof. In some embodiments, the tablet comprises about 2 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis.

[0623] In some embodiments, the tablet comprises about 0.4 mg to about 0.6 mg of the compound of Formula Ila or lib, or a solvate thereof. In some embodiments, the tablet comprises about 0.5 mg to about 0.6 mg of the compound of Formula Ila or lib, or a solvate thereof. In some embodiments, the tablet comprises about 0.5325 mg of the compound of Formula Ila or lib, or a solvate thereof. In some embodiments, the tablet comprises about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis.

[0624] 15 In some embodiments, the tablet comprises about 0.4 mg to about 22 mg of the monohydrate of the compound of Formula Ila or lib. In some embodiments, the tablet comprises about 0.1 mg to about 2.5 mg of the monohydrate of the compound of Formula Ila or lib.

[0625] In some embodiments, the tablet comprises about 2.0 mg to about 2.2 mg of

[0626] 20 the monohydrate of the compound of Formula Ila or lib. In some embodiments, the tablet comprises about 2.1 mg to about 2.2 mg of the monohydrate of the compound of Formula Ila or lib. In some embodiments, the tablet comprises about 2.130 mg of the monohydrate of the compound of Formula Ila or lib.

[0627] In some embodiments, the tablet comprises about 0.4 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib. In some embodiments, the tablet comprises about 0.5 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib. In some embodiments, the tablet comprises about 0.5 mg of the monohydrate of the compound of Formula Ila or lib. In some embodiments, the tablet comprises about 0.5325 mg of the monohydrate of the compound of Formula Ila or

[0628] 30 lib.

[0629] In some embodiments, the tablet comprises: PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0630] 1572-WO-PCT / 35648-0367WO1 PATENT about 300 mg to about 500 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and about 0.4 mg to about 22 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[0631] 5 In some embodiments, the tablet comprises: about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and about 2.1 mg to about 2.2 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[0632] In some embodiments, the tablet comprises: about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and about 2.130 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[0633] 15 In some embodiments, the tablet comprises: about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and about 2.0 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis.

[0634] 20 In some embodiments, the tablet comprises: about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and about 0.5 mg to about 0.6 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[0635] In some embodiments, the tablet comprises: about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and about 0.5325 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[0636] 30 In some embodiments, the tablet comprises: about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0637] 1572-WO-PCT / 35648-0367WO1 PATENT about 0.5 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis.

[0638] In some embodiments, the tablet comprises: about 300 mg to about 500 mg of the compound of Formula la or lb, or a

[0639] 5 pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.4 mg to about 22 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg croscarmellose sodium; and about 20 mg to about 25 mg magnesium stearate.

[0640] In some embodiments, the tablet comprises: about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof;

[0641] 15 about 2.1 mg to about 2.2 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg croscarmellose sodium; and

[0642] 20 about 20 mg to about 25 mg magnesium stearate.

[0643] In some embodiments, the tablet comprises: about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 2.130 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 621 mg of mannitol; about 334.32 mg of microcrystalline cellulose; about 120 mg croscarmellose sodium; and about 22.5 mg magnesium stearate.

[0644] 30 In some embodiments, the tablet comprises: about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0645] 1572-WO-PCT / 35648-0367WO1 PATENT about 2.0 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis; about 621 mg of mannitol; about 334.32 mg of microcrystalline cellulose;

[0646] 5 about 120 mg croscarmellose sodium; and about 22.5 mg magnesium stearate.

[0647] In some embodiments, the tablet comprises: about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.5 mg to about 0.6 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg croscarmellose sodium; and

[0648] 15 about 20 mg to about 25 mg magnesium stearate.

[0649] In some embodiments, the tablet comprises: about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.5325 mg of the compound of Formula Ila or lib, or a pharmaceutically

[0650] 20 acceptable salt, co-crystal, solvate, or combination thereof; about 621 mg of mannitol; about 335.9175 mg of microcrystalline cellulose; about 120 mg croscarmellose sodium; and about 22.5 mg magnesium stearate.

[0651] In some embodiments, the tablet comprises: about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.5 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis;

[0652] 30 about 621 mg of mannitol; about 335.9175 mg of microcrystalline cellulose; about 120 mg croscarmellose sodium; and PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0653] 1572-WO-PCT / 35648-0367WO1 PATENT about 22.5 mg magnesium stearate.

[0654] In some embodiments, the tablet comprises: about 200 mg to about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free

[0655] 5 acid basis; and about 0.4 mg to about 22 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[0656] In some embodiments, the tablet comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis; and about 2.1 mg to about 2.2 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[0657] In some embodiments, the tablet comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically

[0658] 15 acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis; and about 2.130 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[0659] In some embodiments, the tablet comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically

[0660] 20 acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis; and about 2.0 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis.

[0661] In some embodiments, the tablet comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis; and about 0.5 mg to about 0.6 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[0662] In some embodiments, the tablet comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically

[0663] 30 acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis; and about 0.5325 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof. PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0664] 1572-WO-PCT / 35648-0367WO1 PATENT

[0665] In some embodiments, the tablet comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis; and about 0.5 mg of the compound of Formula Ila or lib, or a pharmaceutically

[0666] 5 acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis.

[0667] In some embodiments, the tablet comprises: about 200 mg to about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis; about 0.4 mg to about 22 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg croscarmellose sodium; and

[0668] 15 about 20 mg to about 25 mg magnesium stearate.

[0669] In some embodiments, the tablet comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis; about 2.1 mg to about 2.2 mg of the compound of Formula Ila or lib, or a

[0670] 20 pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg croscarmellose sodium; and about 20 mg to about 25 mg magnesium stearate.

[0671] In some embodiments, the tablet comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis; about 2.130 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof;

[0672] 30 about 621 mg of mannitol; about 334.32 mg of microcrystalline cellulose; about 120 mg croscarmellose sodium; and PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0673] 1572-WO-PCT / 35648-0367WO1 PATENT about 22.5 mg magnesium stearate.

[0674] In some embodiments, the tablet comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis;

[0675] 5 about 2.0 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis; about 621 mg of mannitol; about 334.32 mg of microcrystalline cellulose; about 120 mg croscarmellose sodium; and about 22.5 mg magnesium stearate.

[0676] In some embodiments, the tablet comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis; about 0.5 mg to about 0.6 mg of the compound of Formula Ila or lib, or a

[0677] 15 pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg croscarmellose sodium; and about 20 mg to about 25 mg magnesium stearate.

[0678] 20 In some embodiments, the tablet comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis; about 0.5325 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 621 mg of mannitol; about 335.9175 mg of microcrystalline cellulose; about 120 mg croscarmellose sodium; and about 22.5 mg magnesium stearate.

[0679] In some embodiments, the tablet comprises:

[0680] 30 about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0681] 1572-WO-PCT / 35648-0367WO1 PATENT about 0.5 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis; about 621 mg of mannitol; about 335.9175 mg of microcrystalline cellulose;

[0682] 5 about 120 mg croscarmellose sodium; and about 22.5 mg magnesium stearate.

[0683] In some embodiments, the tablet is about 1000 mg to about 1600 mg, for example, about 1000 mg, about 1050 mg, about 1100 mg, about 1150 mg, about 1200 mg, about 1250 mg, about 1300 mg, about 1350 mg, about 1400 mg, about 1450 mg, about 1500 mg, about 1550 mg, or about 1600 mg. In some embodiments, the tablet is about 1400 mg to about 1600 mg. In some embodiments, the tablet is about 1450 mg to about 1550 mg. In some embodiments, the tablet is about 1500 mg.

[0684] In some embodiments, the tablet comprises: about 200 mg to about 400 mg of the compound of Formula la or lb, or a

[0685] 15 pharmaceutically acceptable salt thereof, on a free acid basis; about 0.1 mg to about 2.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of pol oxamer 407;

[0686] 20 about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0687] In some embodiments, the tablet comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 2 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 65 mg to about 75 mg of copovidone;

[0688] 30 about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0689] 1572-WO-PCT / 35648-0367WO1 PATENT about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0690] In some embodiments, the tablet comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically

[0691] 5 acceptable salt thereof, on a free acid basis; about 2 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 334.32 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; and about 22.5 mg of magnesium stearate.

[0692] In some embodiments, the tablet comprises:

[0693] 15 about 200 mg to about 400 mg of the sodium salt of the compound of Formula la or lb; about 0.1 mg to about 2.5 mg of the monohydrate of the compound of Formula Ila or lib; about 50 mg to about 100 mg of copovidone;

[0694] 20 about 5 mg to about 30 mg of poloxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0695] In some embodiments, the tablet comprises: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 2.1 mg to about 2.2 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone;

[0696] 30 about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0697] 1572-WO-PCT / 35648-0367WO1 PATENT about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0698] In some embodiments, the tablet comprises: about 306.8 mg of the sodium salt of the compound of Formula la or lb;

[0699] 5 about 2.130 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose;

[0700] 10 about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0701] In some embodiments, the tablet comprises: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 2.130 mg of the monohydrate of the compound of Formula Ila or lib; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 334.32 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; and

[0702] 20 about 22.5 mg of magnesium stearate.

[0703] In some embodiments, the tablet comprises: about 200 mg to about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.1 mg to about 2.5 mg of the compound of Formula Ila or lib, or a

[0704] 25 solvate thereof, on a free base basis; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose;

[0705] 30 about 100 mg to about 150 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat. PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0706] 1572-WO-PCT / 35648-0367WO1 PATENT

[0707] In some embodiments, the tablet comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 2 mg of the compound of Formula Ila or lib, or a solvate thereof, on a

[0708] 5 free base basis; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of pol oxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0709] In some embodiments, the tablet comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically

[0710] 15 acceptable salt thereof, on a free acid basis; about 2 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis, on a free base basis; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407;

[0711] 20 about 621 mg of mannitol; about 334.32 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; about 22.5 mg of magnesium stearate; and an outer film coat.

[0712] In some embodiments, the tablet comprises: about 200 mg to about 400 mg of the sodium salt of the compound of Formula la or lb; about 0.1 mg to about 2.5 mg of the monohydrate of the compound of Formula Ila or lib;

[0713] 30 about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407; about 600 mg to about 700 mg of mannitol; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0714] 1572-WO-PCT / 35648-0367WO1 PATENT about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0715] 5 In some embodiments, the tablet comprises: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 2.1 mg to about 2.2 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0716] In some embodiments, the tablet comprises: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 2.130 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0717] In some embodiments, the tablet comprises: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 2.130 mg of the monohydrate of the compound of Formula Ila or lib; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407;

[0718] 30 about 621 mg of mannitol; about 334.32 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0719] 1572-WO-PCT / 35648-0367WO1 PATENT about 22.5 mg of magnesium stearate; and an outer film coat.

[0720] In some embodiments, the tablet consists essentially of: about 200 mg to about 400 mg of the compound of Formula la or lb, or a

[0721] 5 pharmaceutically acceptable salt thereof, on a free acid basis; about 0.1 mg to about 2.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of pol oxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0722] In some embodiments, the tablet consists essentially of:

[0723] 15 about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 2 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 65 mg to about 75 mg of copovidone;

[0724] 20 about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0725] In some embodiments, the tablet consists essentially of: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 2 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis;

[0726] 30 about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0727] 1572-WO-PCT / 35648-0367WO1 PATENT about 334.32 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; and about 22.5 mg of magnesium stearate.

[0728] In some embodiments, the tablet consists essentially of:

[0729] 5 about 200 mg to about 400 mg of the sodium salt of the compound of Formula la or lb; about 0.1 mg to about 2.5 mg of the monohydrate of the compound of Formula Ila or lib; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of pol oxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0730] 15 In some embodiments, the tablet consists essentially of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 2.1 mg to about 2.2 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone;

[0731] 20 about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0732] In some embodiments, the tablet consists essentially of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 2.130 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407;

[0733] 30 about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0734] 1572-WO-PCT / 35648-0367WO1 PATENT about 20 mg to about 25 mg of magnesium stearate.

[0735] In some embodiments, the tablet consists essentially of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 2.130 mg of the monohydrate of the compound of Formula Ila or lib;

[0736] 5 about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 334.32 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; and about 22.5 mg of magnesium stearate.

[0737] In some embodiments, the tablet consists essentially of: about 200 mg to about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.1 mg to about 2.5 mg of the compound of Formula Ila or lib, or a

[0738] 15 solvate thereof, on a free base basis; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose;

[0739] 20 about 100 mg to about 150 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0740] In some embodiments, the tablet consists essentially of: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 2 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407;

[0741] 30 about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0742] 1572-WO-PCT / 35648-0367WO1 PATENT about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0743] In some embodiments, the tablet consists essentially of: about 300 mg of the compound of Formula la or lb, or a pharmaceutically

[0744] 5 acceptable salt thereof, on a free acid basis; about 2 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis, on a free base basis; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 334.32 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; about 22.5 mg of magnesium stearate; and an outer film coat.

[0745] 15 In some embodiments, the tablet consists essentially of: about 200 mg to about 400 mg of the sodium salt of the compound of Formula la or lb; about 0.1 mg to about 2.5 mg of the monohydrate of the compound of Formula Ila or lib;

[0746] 20 about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0747] In some embodiments, the tablet consists essentially of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 2.1 mg to about 2.2 mg of the monohydrate of the compound of Formula

[0748] 30 Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0749] 1572-WO-PCT / 35648-0367WO1 PATENT about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and

[0750] 5 an outer film coat.

[0751] In some embodiments, the tablet consists essentially of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 2.130 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0752] In some embodiments, the tablet consists essentially of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 2.130 mg of the monohydrate of the compound of Formula Ila or lib; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 334.32 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; about 22.5 mg of magnesium stearate; and an outer film coat.

[0753] In some embodiments, the tablet consists of: about 200 mg to about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.1 mg to about 2.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis;

[0754] 30 about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407; about 600 mg to about 700 mg of mannitol; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0755] 1572-WO-PCT / 35648-0367WO1 PATENT about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0756] In some embodiments, the tablet consists of:

[0757] 5 about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 2 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0758] 15 In some embodiments, the tablet consists of: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 2 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis;

[0759] 20 about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 334.32 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; and about 22.5 mg of magnesium stearate.

[0760] In some embodiments, the tablet consists of: about 200 mg to about 400 mg of the sodium salt of the compound of Formula la or lb; about 0.1 mg to about 2.5 mg of the monohydrate of the compound of Formula

[0761] 30 Ila or lib; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0762] 1572-WO-PCT / 35648-0367WO1 PATENT about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0763] 5 In some embodiments, the tablet consists of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 2.1 mg to about 2.2 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0764] In some embodiments, the tablet consists of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 2.130 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0765] In some embodiments, the tablet consists of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 2.130 mg of the monohydrate of the compound of Formula Ila or lib; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol;

[0766] 30 about 334.32 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; and about 22.5 mg of magnesium stearate. PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0767] 1572-WO-PCT / 35648-0367WO1 PATENT

[0768] In some embodiments, the tablet consists of: about 200 mg to about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.1 mg to about 2.5 mg of the compound of Formula Ila or lib, or a

[0769] 5 solvate thereof, on a free base basis; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of pol oxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0770] In some embodiments, the tablet consists of: about 300 mg of the compound of Formula la or lb, or a pharmaceutically

[0771] 15 acceptable salt thereof, on a free acid basis; about 2 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407;

[0772] 20 about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0773] In some embodiments, the tablet consists of: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 2 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis, on a free base basis;

[0774] 30 about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0775] 1572-WO-PCT / 35648-0367WO1 PATENT about 334.32 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; about 22.5 mg of magnesium stearate; and an outer film coat.

[0776] 5 In some embodiments, the tablet consists of: about 200 mg to about 400 mg of the sodium salt of the compound of Formula la or lb; about 0.1 mg to about 2.5 mg of the monohydrate of the compound of Formula Ila or lib; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of pol oxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium;

[0777] 15 about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0778] In some embodiments, the tablet consists of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 2.1 mg to about 2.2 mg of the monohydrate of the compound of Formula

[0779] 20 Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0780] In some embodiments, the tablet consists of: about 306.8 mg of the sodium salt of the compound of Formula la or lb;

[0781] 30 about 2.130 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0782] 1572-WO-PCT / 35648-0367WO1 PATENT about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0783] 5 In some embodiments, the tablet consists of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 2.130 mg of the monohydrate of the compound of Formula Ila or lib; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 334.32 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; about 22.5 mg of magnesium stearate; and an outer film coat.

[0784] 15 In some embodiments, the tablet comprises: about 200 mg to about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.4 mg to about 0.6 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis;

[0785] 20 about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0786] In some embodiments, the tablet comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a

[0787] 30 free base basis; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0788] 1572-WO-PCT / 35648-0367WO1 PATENT about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0789] 5 In some embodiments, the tablet comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; and

[0790] 15 about 22.5 mg of magnesium stearate.

[0791] In some embodiments, the tablet comprises: about 200 mg to about 400 mg of the sodium salt of the compound of Formula la or lb; about 0.4 mg to about 0.6 mg of the monohydrate of the compound of Formula

[0792] 20 Ila or lib; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0793] In some embodiments, the tablet comprises: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.5 mg to about 0.6 mg of the monohydrate of the compound of Formula

[0794] 30 Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0795] 1572-WO-PCT / 35648-0367WO1 PATENT about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0796] 5 In some embodiments, the tablet comprises: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0797] In some embodiments, the tablet comprises:

[0798] 15 about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol;

[0799] 20 about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; and about 22.5 mg of magnesium stearate.

[0800] In some embodiments, the tablet comprises: about 200 mg to about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.4 mg to about 0.6 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407;

[0801] 30 about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0802] 1572-WO-PCT / 35648-0367WO1 PATENT about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0803] In some embodiments, the tablet comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically

[0804] 5 acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0805] 15 In some embodiments, the tablet comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis, on a free base basis;

[0806] 20 about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; about 22.5 mg of magnesium stearate; and an outer film coat.

[0807] In some embodiments, the tablet comprises: about 200 mg to about 400 mg of the sodium salt of the compound of Formula la or lb;

[0808] 30 about 0.4 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib; about 50 mg to about 100 mg of copovidone; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0809] 1572-WO-PCT / 35648-0367WO1 PATENT about 5 mg to about 30 mg of pol oxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium;

[0810] 5 about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0811] In some embodiments, the tablet comprises: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.5 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0812] In some embodiments, the tablet comprises: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0813] In some embodiments, the tablet comprises: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib;

[0814] 30 about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0815] 1572-WO-PCT / 35648-0367WO1 PATENT about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; about 22.5 mg of magnesium stearate; and an outer film coat.

[0816] 5 In some embodiments, the tablet consists essentially of: about 200 mg to about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.4 mg to about 0.6 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of pol oxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; and

[0817] 15 about 20 mg to about 25 mg of magnesium stearate.

[0818] In some embodiments, the tablet consists essentially of: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a

[0819] 20 free base basis; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0820] In some embodiments, the tablet consists essentially of: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis;

[0821] 30 about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 73.2 mg of copovidone; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0822] 1572-WO-PCT / 35648-0367WO1 PATENT about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; and

[0823] 5 about 22.5 mg of magnesium stearate.

[0824] In some embodiments, the tablet consists essentially of: about 200 mg to about 400 mg of the sodium salt of the compound of Formula la or lb; about 0.4 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose;

[0825] 15 about 100 mg to about 150 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0826] In some embodiments, the tablet consists essentially of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.5 mg to about 0.6 mg of the monohydrate of the compound of Formula

[0827] 20 Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0828] In some embodiments, the tablet consists essentially of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib;

[0829] 30 about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0830] 1572-WO-PCT / 35648-0367WO1 PATENT about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0831] In some embodiments, the tablet consists essentially of:

[0832] 5 about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; and about 22.5 mg of magnesium stearate.

[0833] In some embodiments, the tablet consists essentially of: about 200 mg to about 400 mg of the compound of Formula la or lb, or a

[0834] 15 pharmaceutically acceptable salt thereof, on a free acid basis; about 0.4 mg to about 0.6 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407;

[0835] 20 about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0836] In some embodiments, the tablet consists essentially of: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis;

[0837] 30 about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0838] 1572-WO-PCT / 35648-0367WO1 PATENT about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0839] 5 In some embodiments, the tablet consists essentially of: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis, on a free base basis; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium;

[0840] 15 about 22.5 mg of magnesium stearate; and an outer film coat.

[0841] In some embodiments, the tablet consists essentially of: about 200 mg to about 400 mg of the sodium salt of the compound of Formula la or lb;

[0842] 20 about 0.4 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0843] In some embodiments, the tablet consists essentially of:

[0844] 30 about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.5 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0845] 1572-WO-PCT / 35648-0367WO1 PATENT about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose;

[0846] 5 about 115 mg to about 125 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0847] In some embodiments, the tablet consists essentially of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0848] In some embodiments, the tablet consists essentially of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib;

[0849] 20 about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium;

[0850] 25 about 22.5 mg of magnesium stearate; and an outer film coat.

[0851] In some embodiments, the tablet consists of: about 200 mg to about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis;

[0852] 30 about 0.4 mg to about 0.6 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 50 mg to about 100 mg of copovidone; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0853] 1572-WO-PCT / 35648-0367WO1 PATENT about 5 mg to about 30 mg of pol oxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; and

[0854] 5 about 20 mg to about 25 mg of magnesium stearate.

[0855] In some embodiments, the tablet consists of: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose;

[0856] 15 about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0857] In some embodiments, the tablet consists of: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis;

[0858] 20 about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; and about 22.5 mg of magnesium stearate.

[0859] In some embodiments, the tablet consists of: about 200 mg to about 400 mg of the sodium salt of the compound of Formula

[0860] 30 la or lb; about 0.4 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0861] 1572-WO-PCT / 35648-0367WO1 PATENT about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of pol oxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose;

[0862] 5 about 100 mg to about 150 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0863] In some embodiments, the tablet consists of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.5 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0864] In some embodiments, the tablet consists of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0865] In some embodiments, the tablet consists of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; about 73.2 mg of copovidone;

[0866] 30 about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0867] 1572-WO-PCT / 35648-0367WO1 PATENT about 120 mg of croscarmellose sodium; and about 22.5 mg of magnesium stearate.

[0868] In some embodiments, the tablet consists of: about 200 mg to about 400 mg of the compound of Formula la or lb, or a

[0869] 5 pharmaceutically acceptable salt thereof, on a free acid basis; about 0.4 mg to about 0.6 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of pol oxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0870] 15 In some embodiments, the tablet consists of: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis;

[0871] 20 about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0872] In some embodiments, the tablet consists of: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis;

[0873] 30 about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis, on a free base basis; about 73.2 mg of copovidone; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0874] 1572-WO-PCT / 35648-0367WO1 PATENT about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium;

[0875] 5 about 22.5 mg of magnesium stearate; and an outer film coat.

[0876] In some embodiments, the tablet consists of: about 200 mg to about 400 mg of the sodium salt of the compound of Formula la or lb; about 0.4 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407; about 600 mg to about 700 mg of mannitol;

[0877] 15 about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0878] In some embodiments, the tablet consists of:

[0879] 20 about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.5 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0880] 30 In some embodiments, the tablet consists of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0881] 1572-WO-PCT / 35648-0367WO1 PATENT about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose;

[0882] 5 about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0883] In some embodiments, the tablet consists of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium;

[0884] 15 about 22.5 mg of magnesium stearate; and an outer film coat.

[0885] In some embodiments, the tablet comprises: about 200 mg to about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis;

[0886] 20 about 0.4 mg to about 0.6 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0887] In some embodiments, the tablet comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically

[0888] 30 acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0889] 1572-WO-PCT / 35648-0367WO1 PATENT about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose;

[0890] 5 about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0891] In some embodiments, the tablet comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol;

[0892] 15 about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; and about 22.5 mg of magnesium stearate.

[0893] In some embodiments, the tablet comprises: about 200 mg to about 400 mg of the sodium salt of the compound of Formula

[0894] 20 la or lb; about 0.4 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0895] In some embodiments, the tablet comprises:

[0896] 30 about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.5 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0897] 1572-WO-PCT / 35648-0367WO1 PATENT about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose;

[0898] 5 about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0899] In some embodiments, the tablet comprises: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0900] In some embodiments, the tablet comprises: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; about 73.2 mg of copovidone;

[0901] 20 about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; and about 22.5 mg of magnesium stearate.

[0902] 25 In some embodiments, the tablet comprises: about 200 mg to about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.4 mg to about 0.6 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis;

[0903] 30 about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407; about 600 mg to about 700 mg of mannitol; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0904] 1572-WO-PCT / 35648-0367WO1 PATENT about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0905] 5 In some embodiments, the tablet comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium;

[0906] 15 about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0907] In some embodiments, the tablet comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis;

[0908] 20 about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis, on a free base basis; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; about 22.5 mg of magnesium stearate; and an outer film coat.

[0909] In some embodiments, the tablet comprises:

[0910] 30 about 200 mg to about 400 mg of the sodium salt of the compound of Formula la or lb; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0911] 1572-WO-PCT / 35648-0367WO1 PATENT about 0.4 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of pol oxamer 407;

[0912] 5 about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0913] In some embodiments, the tablet comprises: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.5 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone;

[0914] 15 about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and

[0915] 20 an outer film coat.

[0916] In some embodiments, the tablet comprises: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0917] 30 In some embodiments, the tablet comprises: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0918] 1572-WO-PCT / 35648-0367WO1 PATENT about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose;

[0919] 5 about 120 mg of croscarmellose sodium; about 22.5 mg of magnesium stearate; and an outer film coat.

[0920] In some embodiments, the tablet consists essentially of: about 200 mg to about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.4 mg to about 0.6 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407;

[0921] 15 about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0922] In some embodiments, the tablet consists essentially of:

[0923] 20 about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0924] 30 In some embodiments, the tablet consists essentially of: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0925] 1572-WO-PCT / 35648-0367WO1 PATENT about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407;

[0926] 5 about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; and about 22.5 mg of magnesium stearate.

[0927] In some embodiments, the tablet consists essentially of: about 200 mg to about 400 mg of the sodium salt of the compound of Formula la or lb; about 0.4 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib; about 50 mg to about 100 mg of copovidone;

[0928] 15 about 5 mg to about 30 mg of poloxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0929] 20 In some embodiments, the tablet consists essentially of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.5 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0930] 30 In some embodiments, the tablet consists essentially of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0931] 1572-WO-PCT / 35648-0367WO1 PATENT about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose;

[0932] 5 about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0933] In some embodiments, the tablet consists essentially of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; and

[0934] 15 about 22.5 mg of magnesium stearate.

[0935] In some embodiments, the tablet consists essentially of: about 200 mg to about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.4 mg to about 0.6 mg of the compound of Formula Ila or lib, or a

[0936] 20 solvate thereof, on a free base basis; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0937] In some embodiments, the tablet consists essentially of: about 300 mg of the compound of Formula la or lb, or a pharmaceutically

[0938] 30 acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0939] 1572-WO-PCT / 35648-0367WO1 PATENT about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose;

[0940] 5 about 115 mg to about 125 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0941] In some embodiments, the tablet consists essentially of: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis, on a free base basis; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407;

[0942] 15 about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; about 22.5 mg of magnesium stearate; and an outer film coat.

[0943] 20 In some embodiments, the tablet consists essentially of: about 200 mg to about 400 mg of the sodium salt of the compound of Formula la or lb; about 0.4 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium;

[0944] 30 about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0945] In some embodiments, the tablet consists essentially of: PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0946] 1572-WO-PCT / 35648-0367WO1 PATENT about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.5 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone;

[0947] 5 about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0948] In some embodiments, the tablet consists essentially of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone;

[0949] 15 about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0950] 20 In some embodiments, the tablet consists essentially of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; about 22.5 mg of magnesium stearate; and an outer film coat.

[0951] 30 In some embodiments, the tablet consists of: about 200 mg to about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0952] 1572-WO-PCT / 35648-0367WO1 PATENT about 0.4 mg to about 0.6 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of pol oxamer 407;

[0953] 5 about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0954] In some embodiments, the tablet consists of: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 65 mg to about 75 mg of copovidone;

[0955] 15 about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0956] 20 In some embodiments, the tablet consists of: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; and

[0957] 30 about 22.5 mg of magnesium stearate.

[0958] In some embodiments, the tablet consists of: PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0959] 1572-WO-PCT / 35648-0367WO1 PATENT about 200 mg to about 400 mg of the sodium salt of the compound of Formula la or lb; about 0.4 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib;

[0960] 5 about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of pol oxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0961] In some embodiments, the tablet consists of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.5 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib;

[0962] 15 about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and

[0963] 20 about 20 mg to about 25 mg of magnesium stearate.

[0964] In some embodiments, the tablet consists of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0965] 30 In some embodiments, the tablet consists of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0966] 1572-WO-PCT / 35648-0367WO1 PATENT about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose;

[0967] 5 about 120 mg of croscarmellose sodium; and about 22.5 mg of magnesium stearate.

[0968] In some embodiments, the tablet consists of: about 200 mg to about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.4 mg to about 0.6 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407; about 600 mg to about 700 mg of mannitol;

[0969] 15 about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0970] In some embodiments, the tablet consists of:

[0971] 20 about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and

[0972] 30 an outer film coat.

[0973] In some embodiments, the tablet consists of: PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0974] 1572-WO-PCT / 35648-0367WO1 PATENT about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis, on a free base basis;

[0975] 5 about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; about 22.5 mg of magnesium stearate; and an outer film coat.

[0976] In some embodiments, the tablet consists of: about 200 mg to about 400 mg of the sodium salt of the compound of Formula la or lb;

[0977] 15 about 0.4 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407; about 600 mg to about 700 mg of mannitol;

[0978] 20 about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0979] In some embodiments, the tablet consists of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.5 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407;

[0980] 30 about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0981] 1572-WO-PCT / 35648-0367WO1 PATENT about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[0982] In some embodiments, the tablet consists of: about 306.8 mg of the sodium salt of the compound of Formula la or lb;

[0983] 5 about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[0984] In some embodiments, the tablet consists of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib;

[0985] 15 about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium;

[0986] 20 about 22.5 mg of magnesium stearate; and an outer film coat.

[0987] The tablets disclosed herein can be prepared by methodologies known in the pharmaceutical art. The terms “effective amount” or “therapeutically effective amount” refer to an amount of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, and the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, which when administered to a patient in need thereof, is sufficient to effect treating an HIV infection as described herein. Such an amount would be sufficient to elicit the biological or medical response of a tissue system, or

[0988] 30 patient that is sought by a researcher or clinician. The amount of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, and the compound of Formula Ila or Hb, or a pharmaceutically PCT / US25 / 44161 29 August 2025 (29.08.2025)

[0989] 1572-WO-PCT / 35648-0367WO1 PATENT acceptable salt, co-crystal, solvate, or combination thereof, which constitutes a therapeutically effective amount will vary depending on such factors as the compound, salt, free acid, or composition used for administration, the time of administration, the route of administration, the rate of excretion of the compound, the

[0990] 5 duration of the treatment, the type of disease-state or disorder being treated and its severity, and the age, body weight, general health, sex and diet of the patient. Such a therapeutically effective amount can be determined routinely by one of ordinary skill in the art having regard to their own knowledge, the state of the art, and this disclosure.

[0991] Methods of Use

[0992] In some embodiments, the methods provided herein comprise treating a human immunodeficiency virus (HIV) infection in the patient. In some embodiments, the methods provided herein comprise treating a HIV infection in the patient. In some

[0993] 15 embodiments, the HIV is HIV-1. In some embodiments, the HIV is HIV-2. In some embodiments, the HIV is HIV-1 and HIV-2.

[0994] As used herein, “HIV” or “Human Immunodeficiency Virus” refers to HIV-1 and / or to HIV-2.

[0995] The term “patient” is meant to refer to a human who is in need of therapeutic

[0996] 20 treatment for a viral infection, such as HIV infection.

[0997] Administration of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, and compound of Formula Ila or Hb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, can be carried out via any of the accepted modes of administration of agents for serving similar utilities. In some embodiments, the administration is oral administration.

[0998] In some embodiments, the methods provided herein further comprise administering one or more initiation (z.e., loading) doses of the tablet provided herein, for a first period of time.

[0999] 30 In some embodiments, the first period of time is about one day to about 10 days. In some embodiments, the first period of time is one day. In some embodiments, the first period of time is two days. PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1000] 1572-WO-PCT / 35648-0367WO1 PATENT

[1001] In some embodiments, the initiation dosage provided herein comprises one or more oral administrations of a tablet provided herein.

[1002] In some embodiments, the initiation dosage is administered orally as one or two tablets provided herein (e.g., one or two tablets on day 1; one or two tablets on

[1003] 5 day 2; one or two tablets on day 1 and one or two tablets on day 2; and the like). In some embodiments, the oral administrations are administered as two tablets provided herein.

[1004] In some embodiments, the initiation dosage is administered orally as two tablets provided herein on day 1; and as two tablets provided herein on day 2.

[1005] In some embodiments, each tablet of the initiation dosage comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib,

[1006] 15 or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[1007] In some embodiments, each tablet of the initiation dosage comprises: about 26.67 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination

[1008] 20 thereof; about 0.0355 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[1009] In some embodiments, each tablet of the initiation dosage comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof; and

[1010] 30 one or more pharmaceutically acceptable excipients.

[1011] In some embodiments, each tablet of the initiation dosage comprises: PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1012] 1572-WO-PCT / 35648-0367WO1 PATENT about 26.67 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.0355 w / w% of the compound of Formula Ila or lib, or a solvate

[1013] 5 thereof; and one or more pharmaceutically acceptable excipients.

[1014] In some embodiments, each tablet of the initiation dosage comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib; and one or more pharmaceutically acceptable excipients.

[1015] In some embodiments, each tablet of the initiation dosage comprises:

[1016] 15 about 26.67 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.0355 w / w% of the monohydrate of the compound of Formula Ila or lib; and

[1017] 20 one or more pharmaceutically acceptable excipients.

[1018] In some embodiments, each tablet of the initiation dosage comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and

[1019] 30 about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[1020] In some embodiments, each tablet of the initiation dosage comprises: PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1021] 1572-WO-PCT / 35648-0367WO1 PATENT about 26.67 w / w% of the compound of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.0355 w / w% of the compound of Formula Ila or lib, or a

[1022] 5 pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.4 w / w% of mannitol; about 22.3945 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[1023] In some embodiments, each tablet of the initiation dosage comprises: about 19 w / w% to about 21 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof;

[1024] 15 about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; and

[1025] 20 about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[1026] In some embodiments, each tablet of the initiation dosage comprises: about 19.8 w / w% to about 20.8 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose;

[1027] 30 about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[1028] In some embodiments, each tablet of the initiation dosage comprises: PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1029] 1572-WO-PCT / 35648-0367WO1 PATENT about 20.46 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.0355 w / w% of the compound of Formula Ila or lib, or a solvate thereof;

[1030] 5 about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.395 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[1031] In some embodiments, each tablet of the initiation dosage comprises: about 19 w / w% to about 21 w / w% of the sodium salt of the compound of Formula la or lb; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of

[1032] 15 Formula Ila or lib; about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose;

[1033] 20 about 7 w / w% to about 9 w / w% of croscarmellose sodium; and about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[1034] In some embodiments, each tablet of the initiation dosage comprises: about 19.8 w / w% to about 20.8 w / w% of the sodium salt of the compound of Formula la or lb; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407; about 41 w / w% to about 42 w / w% of mannitol;

[1035] 30 about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate. PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1036] 1572-WO-PCT / 35648-0367WO1 PATENT

[1037] In some embodiments, each tablet of the initiation dosage comprises: about 20.46 w / w% of the sodium salt of the compound of Formula la or lb; about 0.0355 w / w% of the monohydrate of the compound of Formula Ila or lib;

[1038] 5 about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.395 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[1039] In some embodiments, each tablet of the initiation dosage comprises: about 19 w / w% to about 21 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib,

[1040] 15 or a solvate thereof; about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose;

[1041] 20 about 7 w / w% to about 9 w / w% of croscarmellose sodium; about 1.0 w / w% to about 2.0 w / w% of magnesium stearate; and an outer film coat.

[1042] In some embodiments, each tablet of the initiation dosage comprises: about 19.8 w / w% to about 20.8 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407;

[1043] 30 about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1044] 1572-WO-PCT / 35648-0367WO1 PATENT about 1.4 w / w% to about 1.6 w / w% of magnesium stearate; and an outer film coat.

[1045] In some embodiments, each tablet of the initiation dosage comprises: about 20.46 w / w% of the compound of Formula la or lb, or a

[1046] 5 pharmaceutically acceptable salt thereof; about 0.0355 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.395 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; about 1.5 w / w% of magnesium stearate; and an outer film coat.

[1047] 15 In some embodiments, each tablet of the initiation dosage comprises: about 19 w / w% to about 21 w / w% of the sodium salt of the compound of Formula la or lb; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib;

[1048] 20 about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; about 1.0 w / w% to about 2.0 w / w% of magnesium stearate; and an outer film coat.

[1049] In some embodiments, each tablet of the initiation dosage comprises: about 19.8 w / w% to about 20.8 w / w% of the sodium salt of the compound of Formula la or lb;

[1050] 30 about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 5 w / w% of copovidone; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1051] 1572-WO-PCT / 35648-0367WO1 PATENT about 1 w / w% to about 2 w / w% of pol oxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium;

[1052] 5 about 1.4 w / w% to about 1.6 w / w% of magnesium stearate; and an outer film coat.

[1053] In some embodiments, each tablet of the initiation dosage comprises: about 20.46 w / w% of the sodium salt of the compound of Formula la or lb; about 0.0355 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.395 w / w% of microcrystalline cellulose;

[1054] 15 about 8.0 w / w% of croscarmellose sodium; about 1.5 w / w% of magnesium stearate; and an outer film coat.

[1055] In some embodiments, each tablet of the initiation dosage consists essentially of:

[1056] 20 about 19 w / w% to about 21 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; and about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[1057] 30 In some embodiments, each tablet of the initiation dosage consists essentially of: PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1058] 1572-WO-PCT / 35648-0367WO1 PATENT about 19.8 w / w% to about 20.8 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof;

[1059] 5 about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of pol oxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[1060] In some embodiments, each tablet of the initiation dosage consists essentially of: about 20.46 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof;

[1061] 15 about 0.0355 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol;

[1062] 20 about 22.395 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[1063] In some embodiments, each tablet of the initiation dosage consists essentially of: about 19 w / w% to about 21 w / w% of the sodium salt of the compound of Formula la or lb; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 6 w / w% of copovidone;

[1064] 30 about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1065] 1572-WO-PCT / 35648-0367WO1 PATENT about 7 w / w% to about 9 w / w% of croscarmellose sodium; and about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[1066] In some embodiments, each tablet of the initiation dosage consists essentially of:

[1067] 5 about 19.8 w / w% to about 20.8 w / w% of the sodium salt of the compound of Formula la or lb; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of pol oxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[1068] 15 In some embodiments, each tablet of the initiation dosage consists essentially of: about 20.46 w / w% of the sodium salt of the compound of Formula la or lb; about 0.0355 w / w% of the monohydrate of the compound of Formula Ila or lib;

[1069] 20 about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.395 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[1070] In some embodiments, each tablet of the initiation dosage consists essentially of: about 19 w / w% to about 21 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof;

[1071] 30 about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 6 w / w% of copovidone; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1072] 1572-WO-PCT / 35648-0367WO1 PATENT about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium;

[1073] 5 about 1.0 w / w% to about 2.0 w / w% of magnesium stearate; and an outer film coat.

[1074] In some embodiments, each tablet of the initiation dosage consists essentially of: about 19.8 w / w% to about 20.8 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407;

[1075] 15 about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; about 1.4 w / w% to about 1.6 w / w% of magnesium stearate; and an outer film coat.

[1076] 20 In some embodiments, each tablet of the initiation dosage consists essentially of: about 20.46 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.0355 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4.88 w / w% of copovidone; about 1.33 w / w% of poloxamer 407; about 41.40 w / w% of mannitol; about 22.395 w / w% of microcrystalline cellulose;

[1077] 30 about 8.0 w / w% of croscarmellose sodium; about 1.5 w / w% of magnesium stearate; and an outer film coat. PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1078] 1572-WO-PCT / 35648-0367WO1 PATENT

[1079] In some embodiments, each tablet of the initiation dosage consists essentially of: about 19 w / w% to about 21 w / w% of the sodium salt of the compound of Formula la or lb;

[1080] 5 about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; about 1.0 w / w% to about 2.0 w / w% of magnesium stearate; and an outer film coat.

[1081] In some embodiments, each tablet of the initiation dosage consists essentially

[1082] 15 of: about 19.8 w / w% to about 20.8 w / w% of the sodium salt of the compound of Formula la or lb; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib;

[1083] 20 about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; about 1.4 w / w% to about 1.6 w / w% of magnesium stearate; and an outer film coat.

[1084] In some embodiments, each tablet of the initiation dosage consists essentially of: about 20.46 w / w% of the sodium salt of the compound of Formula la or lb;

[1085] 30 about 0.0355 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4.88 w / w% of copovidone; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1086] 1572-WO-PCT / 35648-0367WO1 PATENT about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.395 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium;

[1087] 5 about 1.5 w / w% of magnesium stearate; and an outer film coat.

[1088] In some embodiments, each tablet of the initiation dosage consists of: about 19 w / w% to about 21 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol;

[1089] 15 about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; and about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[1090] In some embodiments, each tablet of the initiation dosage consists of: about 19.8 w / w% to about 20.8 w / w% of the compound of Formula la or lb, or

[1091] 20 a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[1092] In some embodiments, each tablet of the initiation dosage consists of:

[1093] 30 about 20.46 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1094] 1572-WO-PCT / 35648-0367WO1 PATENT about 0.0355 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407;

[1095] 5 about 41.40 w / w% of mannitol; about 22.395 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[1096] In some embodiments, each tablet of the initiation dosage consists of: about 19 w / w% to about 21 w / w% of the sodium salt of the compound of Formula la or lb; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 6 w / w% of copovidone;

[1097] 15 about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; and about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

[1098] 20 In some embodiments, each tablet of the initiation dosage consists of: about 19.8 w / w% to about 20.8 w / w% of the sodium salt of the compound of Formula la or lb; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and

[1099] 30 about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[1100] In some embodiments, each tablet of the initiation dosage consists of: about 20.46 w / w% of the sodium salt of the compound of Formula la or lb; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1101] 1572-WO-PCT / 35648-0367WO1 PATENT about 0.0355 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407;

[1102] 5 about 41.40 w / w% of mannitol; about 22.395 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[1103] In some embodiments, each tablet of the initiation dosage consists of: about 19 w / w% to about 21 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 6 w / w% of copovidone;

[1104] 15 about 0.1 w / w% to about 2 w / w% of poloxamer 407; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; about 1.0 w / w% to about 2.0 w / w% of magnesium stearate; and

[1105] 20 an outer film coat.

[1106] In some embodiments, each tablet of the initiation dosage consists of: about 19.8 w / w% to about 20.8 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof; about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose;

[1107] 30 about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; about 1.4 w / w% to about 1.6 w / w% of magnesium stearate; and an outer film coat. PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1108] 1572-WO-PCT / 35648-0367WO1 PATENT

[1109] In some embodiments, each tablet of the initiation dosage consists of: about 20.46 w / w% of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.0355 w / w% of the compound of Formula Ila or lib, or a solvate

[1110] 5 thereof; about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.395 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; about 1.5 w / w% of magnesium stearate; and an outer film coat.

[1111] In some embodiments, each tablet of the initiation dosage consists of: about 19 w / w% to about 21 w / w% of the sodium salt of the compound of

[1112] 15 Formula la or lb; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4 w / w% to about 6 w / w% of copovidone; about 0.1 w / w% to about 2 w / w% of poloxamer 407;

[1113] 20 about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; about 1.0 w / w% to about 2.0 w / w% of magnesium stearate; and an outer film coat.

[1114] In some embodiments, each tablet of the initiation dosage consists of: about 19.8 w / w% to about 20.8 w / w% of the sodium salt of the compound of Formula la or lb; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib;

[1115] 30 about 4 w / w% to about 5 w / w% of copovidone; about 1 w / w% to about 2 w / w% of poloxamer 407; about 41 w / w% to about 42 w / w% of mannitol; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1116] 1572-WO-PCT / 35648-0367WO1 PATENT about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; about 1.4 w / w% to about 1.6 w / w% of magnesium stearate; and an outer film coat.

[1117] 5 In some embodiments, each tablet of the initiation dosage consists of: about 20.46 w / w% of the sodium salt of the compound of Formula la or lb; about 0.0355 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.395 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; about 1.5 w / w% of magnesium stearate; and

[1118] 15 an outer film coat.

[1119] In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and

[1120] 20 about 0.5 mg to about 0.6 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[1121] In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and about 0.5325 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[1122] In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the compound of Formula la or

[1123] 30 lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1124] 1572-WO-PCT / 35648-0367WO1 PATENT about 0.5 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis.

[1125] In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the compound of Formula la or

[1126] 5 lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.5 mg to about 0.6 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg croscarmellose sodium; and about 20 mg to about 25 mg magnesium stearate.

[1127] In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof;

[1128] 15 about 0.5325 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 621 mg of mannitol; about 335.9175 mg of microcrystalline cellulose; about 120 mg croscarmellose sodium; and

[1129] 20 about 22.5 mg magnesium stearate.

[1130] In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.5 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis; about 621 mg of mannitol; about 335.9175 mg of microcrystalline cellulose; about 120 mg croscarmellose sodium; and about 22.5 mg magnesium stearate.

[1131] 30 In some embodiments, each tablet of the initiation dosage comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1132] 1572-WO-PCT / 35648-0367WO1 PATENT about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[1133] In some embodiments, each tablet of the initiation dosage comprises:

[1134] 5 about 26.67 w / w% of the spray dried dispersion of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.0355 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[1135] In some embodiments, each tablet of the initiation dosage comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof; and

[1136] 15 one or more pharmaceutically acceptable excipients.

[1137] In some embodiments, each tablet of the initiation dosage comprises: about 26.67 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.0355 w / w% of the compound of Formula Ila or lib, or a solvate

[1138] 20 thereof; and one or more pharmaceutically acceptable excipients.

[1139] In some embodiments, each tablet of the initiation dosage comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib; and one or more pharmaceutically acceptable excipients.

[1140] In some embodiments, each tablet of the initiation dosage comprises: about 26.67 w / w% of the spray dried dispersion of the compound of Formula

[1141] 30 la or lb, or a pharmaceutically acceptable salt thereof; about 0.0355 w / w% of the monohydrate of the compound of Formula Ila or lib; and PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1142] 1572-WO-PCT / 35648-0367WO1 PATENT one or more pharmaceutically acceptable excipients.

[1143] In some embodiments, each tablet of the initiation dosage comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof;

[1144] 5 about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[1145] In some embodiments, each tablet of the initiation dosage comprises: about 26.67 w / w% of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.0355 w / w% of the compound of Formula Ila or lib, or a

[1146] 15 pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.4 w / w% of mannitol; about 22.3945 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[1147] 20 In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; and about 0.5 mg to about 0.6 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[1148] In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; and about 0.5325 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[1149] 30 In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; and PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1150] 1572-WO-PCT / 35648-0367WO1 PATENT about 0.5 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis.

[1151] In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the compound of Formula la or

[1152] 5 lb, or a pharmaceutically acceptable salt thereof; about 0.5 mg to about 0.6 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg croscarmellose sodium; and about 20 mg to about 25 mg magnesium stearate.

[1153] In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof;

[1154] 15 about 0.5325 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 621 mg of mannitol; about 335.9175 mg of microcrystalline cellulose; about 120 mg croscarmellose sodium; and

[1155] 20 about 22.5 mg magnesium stearate.

[1156] In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof; about 0.5 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis; about 621 mg of mannitol; about 335.9175 mg of microcrystalline cellulose; about 120 mg croscarmellose sodium; and about 22.5 mg magnesium stearate.

[1157] 30 In some embodiments, each tablet of the initiation dosage comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la or lb; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1158] 1572-WO-PCT / 35648-0367WO1 PATENT about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[1159] In some embodiments, each tablet of the initiation dosage comprises:

[1160] 5 about 26.67 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la or lb; about 0.0355 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[1161] In some embodiments, each tablet of the initiation dosage comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la or lb; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof; and

[1162] 15 one or more pharmaceutically acceptable excipients.

[1163] In some embodiments, each tablet of the initiation dosage comprises: about 26.67 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la or lb; about 0.0355 w / w% of the compound of Formula Ila or lib, or a solvate

[1164] 20 thereof; and one or more pharmaceutically acceptable excipients.

[1165] In some embodiments, each tablet of the initiation dosage comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la or lb; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib; and one or more pharmaceutically acceptable excipients.

[1166] In some embodiments, each tablet of the initiation dosage comprises: about 26.67 w / w% of the spray dried dispersion of the sodium salt of the

[1167] 30 compound of Formula la or lb; about 0.0355 w / w% of the monohydrate of the compound of Formula Ila or lib; and PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1168] 1572-WO-PCT / 35648-0367WO1 PATENT one or more pharmaceutically acceptable excipients.

[1169] In some embodiments, each tablet of the initiation dosage comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la or lb;

[1170] 5 about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[1171] In some embodiments, each tablet of the initiation dosage comprises: about 26.67 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la or lb; about 0.0355 w / w% of the compound of Formula Ila or lib, or a

[1172] 15 pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.4 w / w% of mannitol; about 22.3945 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[1173] 20 In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the sodium salt of the compound of Formula la or lb; and about 0.5 mg to about 0.6 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[1174] In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the sodium salt of the compound of Formula la or lb; and about 0.5325 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[1175] 30 In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the sodium salt of the compound of Formula la or lb; and PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1176] 1572-WO-PCT / 35648-0367WO1 PATENT about 0.5 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis.

[1177] In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the sodium salt of the compound

[1178] 5 of Formula la or lb; about 0.5 mg to about 0.6 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg croscarmellose sodium; and about 20 mg to about 25 mg magnesium stearate.

[1179] In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the sodium salt of the compound of Formula la or lb;

[1180] 15 about 0.5325 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 621 mg of mannitol; about 335.9175 mg of microcrystalline cellulose; about 120 mg croscarmellose sodium; and

[1181] 20 about 22.5 mg magnesium stearate.

[1182] In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the sodium salt of the compound of Formula la or lb; about 0.5 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis; about 621 mg of mannitol; about 335.9175 mg of microcrystalline cellulose; about 120 mg croscarmellose sodium; and about 22.5 mg magnesium stearate.

[1183] 30 In some embodiments, each tablet of the initiation dosage comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1184] 1572-WO-PCT / 35648-0367WO1 PATENT about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[1185] In some embodiments, each tablet of the initiation dosage comprises:

[1186] 5 about 26.67 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la; about 0.0355 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[1187] In some embodiments, each tablet of the initiation dosage comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof; and

[1188] 15 one or more pharmaceutically acceptable excipients.

[1189] In some embodiments, each tablet of the initiation dosage comprises: about 26.67 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la; about 0.0355 w / w% of the compound of Formula Ila or lib, or a solvate

[1190] 20 thereof; and one or more pharmaceutically acceptable excipients.

[1191] In some embodiments, each tablet of the initiation dosage comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib; and one or more pharmaceutically acceptable excipients.

[1192] In some embodiments, each tablet of the initiation dosage comprises: about 26.67 w / w% of the spray dried dispersion of the sodium salt of the

[1193] 30 compound of Formula la; about 0.0355 w / w% of the monohydrate of the compound of Formula Ila or lib; and PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1194] 1572-WO-PCT / 35648-0367WO1 PATENT one or more pharmaceutically acceptable excipients.

[1195] In some embodiments, each tablet of the initiation dosage comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la;

[1196] 5 about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[1197] In some embodiments, each tablet of the initiation dosage comprises: about 26.67 w / w% of the spray dried dispersion of the sodium salt of the compound of Formula la; about 0.0355 w / w% of the compound of Formula Ila or lib, or a

[1198] 15 pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.4 w / w% of mannitol; about 22.3945 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[1199] 20 In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the sodium salt of the compound of Formula la; and about 0.5 mg to about 0.6 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[1200] In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the sodium salt of the compound of Formula la; and about 0.5325 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[1201] 30 In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the sodium salt of the compound of Formula la; and PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1202] 1572-WO-PCT / 35648-0367WO1 PATENT about 0.5 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis.

[1203] In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the sodium salt of the compound

[1204] 5 of Formula la; about 0.5 mg to about 0.6 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg croscarmellose sodium; and about 20 mg to about 25 mg magnesium stearate.

[1205] In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the sodium salt of the compound of Formula la;

[1206] 15 about 0.5325 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 621 mg of mannitol; about 335.9175 mg of microcrystalline cellulose; about 120 mg croscarmellose sodium; and

[1207] 20 about 22.5 mg magnesium stearate.

[1208] In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the spray dried dispersion of the sodium salt of the compound of Formula la; about 0.5 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis; about 621 mg of mannitol; about 335.9175 mg of microcrystalline cellulose; about 120 mg croscarmellose sodium; and about 22.5 mg magnesium stearate.

[1209] 30 In some embodiments, each tablet of the initiation dosage comprises: about 26.6 w / w% to about 26.7 w / w% of the lenacapavir spray dried dispersion; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1210] 1572-WO-PCT / 35648-0367WO1 PATENT about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[1211] In some embodiments, each tablet of the initiation dosage comprises:

[1212] 5 about 26.67 w / w% of the lenacapavir spray dried dispersion; about 0.0355 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

[1213] In some embodiments, each tablet of the initiation dosage comprises: about 26.6 w / w% to about 26.7 w / w% of the lenacapavir spray dried dispersion; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a solvate thereof; and one or more pharmaceutically acceptable excipients.

[1214] 15 In some embodiments, each tablet of the initiation dosage comprises: about 26.67 w / w% of the lenacapavir spray dried dispersion; about 0.0355 w / w% of the compound of Formula Ila or lib, or a solvate thereof; and one or more pharmaceutically acceptable excipients.

[1215] 20 In some embodiments, each tablet of the initiation dosage comprises: about 26.6 w / w% to about 26.7 w / w% of the lenacapavir spray dried dispersion; about 0.03 w / w% to about 0.04 w / w% of the monohydrate of the compound of Formula Ila or lib; and one or more pharmaceutically acceptable excipients.

[1216] In some embodiments, each tablet of the initiation dosage comprises: about 26.67 w / w% of the lenacapavir spray dried dispersion; about 0.0355 w / w% of the monohydrate of the compound of Formula Ila or lib; and

[1217] 30 one or more pharmaceutically acceptable excipients.

[1218] In some embodiments, each tablet of the initiation dosage comprises: PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1219] 1572-WO-PCT / 35648-0367WO1 PATENT about 26.6 w / w% to about 26.7 w / w% of the lenacapavir spray dried dispersion; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof;

[1220] 5 about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

[1221] In some embodiments, each tablet of the initiation dosage comprises: about 26.67 w / w% of the compound of the lenacapavir spray dried dispersion; about 0.0355 w / w% of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.4 w / w% of mannitol; about 22.3945 w / w% of microcrystalline cellulose;

[1222] 15 about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

[1223] In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the lenacapavir spray dried dispersion; and about 0.5 mg to about 0.6 mg of the compound of Formula Ila or lib, or a

[1224] 20 pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[1225] In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the lenacapavir spray dried dispersion; and about 0.5325 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[1226] In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the lenacapavir spray dried dispersion; and about 0.5 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis.

[1227] In some embodiments, each tablet of the initiation dosage comprises:

[1228] 30 about 400 mg of the lenacapavir spray dried dispersion; about 0.5 mg to about 0.6 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1229] 1572-WO-PCT / 35648-0367WO1 PATENT about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg croscarmellose sodium; and about 20 mg to about 25 mg magnesium stearate.

[1230] 5 In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the lenacapavir spray dried dispersion; about 0.5325 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 621 mg of mannitol; about 335.9175 mg of microcrystalline cellulose; about 120 mg croscarmellose sodium; and about 22.5 mg magnesium stearate.

[1231] In some embodiments, each tablet of the initiation dosage comprises: about 400 mg of the lenacapavir spray dried dispersion;

[1232] 15 about 0.5 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis; about 621 mg of mannitol; about 335.9175 mg of microcrystalline cellulose; about 120 mg croscarmellose sodium; and

[1233] 20 about 22.5 mg magnesium stearate.

[1234] In some embodiments, each tablet of the initiation dosage comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis; and about 0.5 mg to about 0.6 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

[1235] In some embodiments, each tablet of the initiation dosage comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis; and about 0.5325 mg of the compound of Formula Ila or lib, or a pharmaceutically

[1236] 30 acceptable salt, co-crystal, solvate, or combination thereof.

[1237] In some embodiments, each tablet of the initiation dosage comprises: PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1238] 1572-WO-PCT / 35648-0367WO1 PATENT about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis; and about 0.5 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis.

[1239] 5 In some embodiments, each tablet of the initiation dosage comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis; about 0.5 mg to about 0.6 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg croscarmellose sodium; and about 20 mg to about 25 mg magnesium stearate.

[1240] In some embodiments, each tablet of the initiation dosage comprises:

[1241] 15 about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis; about 0.5325 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 621 mg of mannitol;

[1242] 20 about 335.9175 mg of microcrystalline cellulose; about 120 mg croscarmellose sodium; and about 22.5 mg magnesium stearate.

[1243] In some embodiments, each tablet of the initiation dosage comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis; about 621 mg of mannitol; about 335.9175 mg of microcrystalline cellulose;

[1244] 30 about 120 mg croscarmellose sodium; and about 22.5 mg magnesium stearate.

[1245] In some embodiments, each tablet of the initiation dosage comprises: PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1246] 1572-WO-PCT / 35648-0367WO1 PATENT about 200 mg to about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.4 mg to about 0.6 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis;

[1247] 5 about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of pol oxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[1248] In some embodiments, each tablet of the initiation dosage comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a

[1249] 15 free base basis; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose;

[1250] 20 about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[1251] In some embodiments, each tablet of the initiation dosage comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol;

[1252] 30 about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; and about 22.5 mg of magnesium stearate. PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1253] 1572-WO-PCT / 35648-0367WO1 PATENT

[1254] In some embodiments, each tablet of the initiation dosage comprises: about 200 mg to about 400 mg of the sodium salt of the compound of Formula la or lb; about 0.4 mg to about 0.6 mg of the monohydrate of the compound of Formula

[1255] 5 Ila or lib; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of pol oxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[1256] In some embodiments, each tablet of the initiation dosage comprises: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.5 mg to about 0.6 mg of the monohydrate of the compound of Formula

[1257] 15 Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose;

[1258] 20 about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[1259] In some embodiments, each tablet of the initiation dosage comprises: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and

[1260] 30 about 20 mg to about 25 mg of magnesium stearate.

[1261] In some embodiments, each tablet of the initiation dosage comprises: about 306.8 mg of the sodium salt of the compound of Formula la or lb; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1262] 1572-WO-PCT / 35648-0367WO1 PATENT about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol;

[1263] 5 about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; and about 22.5 mg of magnesium stearate.

[1264] In some embodiments, each tablet of the initiation dosage comprises: about 200 mg to about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.4 mg to about 0.6 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407;

[1265] 15 about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[1266] 20 In some embodiments, each tablet of the initiation dosage comprises: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium;

[1267] 30 about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[1268] In some embodiments, each tablet of the initiation dosage comprises: PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1269] 1572-WO-PCT / 35648-0367WO1 PATENT about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis, on a free base basis;

[1270] 5 about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; about 22.5 mg of magnesium stearate; and an outer film coat.

[1271] In some embodiments, each tablet of the initiation dosage comprises: about 200 mg to about 400 mg of the sodium salt of the compound of Formula la or lb;

[1272] 15 about 0.4 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407; about 600 mg to about 700 mg of mannitol;

[1273] 20 about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[1274] In some embodiments, each tablet of the initiation dosage comprises: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.5 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407;

[1275] 30 about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1276] 1572-WO-PCT / 35648-0367WO1 PATENT about 20 mg to about 25 mg of magnesium stearate; and an outer film coat.

[1277] In some embodiments, each tablet of the initiation dosage comprises: about 306.8 mg of the sodium salt of the compound of Formula la or lb;

[1278] 5 about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[1279] In some embodiments, each tablet of the initiation dosage comprises: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.53 mg of the monohydrate of the compound of Formula Ila or lib;

[1280] 15 about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium;

[1281] 20 about 22.5 mg of magnesium stearate; and an outer film coat.

[1282] In some embodiments, each tablet of the initiation dosage consists essentially of: about 200 mg to about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.4 mg to about 0.6 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of poloxamer 407;

[1283] 30 about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; and PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1284] 1572-WO-PCT / 35648-0367WO1 PATENT about 20 mg to about 25 mg of magnesium stearate.

[1285] In some embodiments, each tablet of the initiation dosage consists essentially of: about 300 mg of the compound of Formula la or lb, or a pharmaceutically

[1286] 5 acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[1287] In some embodiments, each tablet of the initiation dosage consists essentially

[1288] 15 of: about 300 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.5 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis;

[1289] 20 about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; and about 22.5 mg of magnesium stearate.

[1290] In some embodiments, each tablet of the initiation dosage consists essentially of: about 200 mg to about 400 mg of the sodium salt of the compound of Formula la or lb;

[1291] 30 about 0.4 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib; about 50 mg to about 100 mg of copovidone; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1292] 1572-WO-PCT / 35648-0367WO1 PATENT about 5 mg to about 30 mg of pol oxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose; about 100 mg to about 150 mg of croscarmellose sodium; and

[1293] 5 about 20 mg to about 25 mg of magnesium stearate.

[1294] In some embodiments, each tablet of the initiation dosage consists essentially of: about 306.8 mg of the sodium salt of the compound of Formula la or lb; about 0.5 mg to about 0.6 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose;

[1295] 15 about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[1296] In some embodiments, each tablet of the initiation dosage consists essentially of: about 306.8 mg of the sodium salt of the compound of Formula la or lb;

[1297] 20 about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; about 65 mg to about 75 mg of copovidone; about 15 mg to about 25 mg of poloxamer 407; about 615 mg to about 625 mg of mannitol; about 330 mg to about 340 mg of microcrystalline cellulose; about 115 mg to about 125 mg of croscarmellose sodium; and about 20 mg to about 25 mg of magnesium stearate.

[1298] In some embodiments, each tablet of the initiation dosage consists essentially of: about 306.8 mg of the sodium salt of the compound of Formula la or lb;

[1299] 30 about 0.53 mg of the monohydrate of the compound of Formula Ila or lib; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; PCT / US25 / 44161 29 August 2025 (29.08.2025)

[1300] 1572-WO-PCT / 35648-0367WO1 PATENT about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; and about 22.5 mg of magnesium stearate.

[1301] 5 In some embodiments, each tablet of the initiation dosage consists essentially of: about 200 mg to about 400 mg of the compound of Formula la or lb, or a pharmaceutically acceptable salt thereof, on a free acid basis; about 0.4 mg to about 0.6 mg of the compound of Formula Ila or lib, or a solvate thereof, on a free base basis; about 50 mg to about 100 mg of copovidone; about 5 mg to about 30 mg of pol oxamer 407; about 600 mg to about 700 mg of mannitol; about 300 mg to about 350 mg of microcrystalline cellulose;[1...

Claims

1. 1572-WO-PCT / 35648-0367WO1 PATENTWHAT IS CLAIMED IS:

1. A tablet, comprising a compound of Formula la:or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; a compound of Formula Ila:Ila or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and one or more pharmaceutically acceptable excipients.

2. The tablet of claim 1, wherein the tablet comprises a spray dried dispersion of the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, wherein the spray dried dispersion comprises about 76.7 w / w% of the compound of Formula la, or a pharmaceutically acceptable salt, cocrystal, solvate, or combination thereof, about 18.3 w / w% copovidone, and about 5.0 w / w% poloxamer 407.

3. The tablet of claim 2, wherein the tablet comprises about 26 w / w% to about 27 w / w% of the spray dried dispersion of the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.1572-WO-PCT / 35648-0367WO1 PATENT4. The tablet of claim 2, wherein the tablet comprises about 26.6 w / w% to about26.7 w / w% of the spray dried dispersion of the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

5. The tablet of any one of claims 1 to 4, wherein the tablet comprises about 0.01 w / w% to about 2.0 w / w% of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

6. The tablet of any one of claims 1 to 4, wherein the tablet comprises about 0.02 w / w% to about 0.2 w / w% of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

7. The tablet of any one of claims 1 to 4, wherein the tablet comprises about 0.03 w / w% to about 0.15 w / w% of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

8. The tablet of any one of claims 1 to 4, wherein the tablet comprises about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

9. The tablet of any one of claims 1 to 4, wherein the tablet comprises about 0.142 w / w% of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

10. The tablet of any one of claims 1 to 4, wherein the tablet comprises about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

11. The tablet of any one of claims 1 to 4, wherein the tablet comprises about 0.0355 w / w% of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.1572-WO-PCT / 35648-0367WO1 PATENT12. The tablet of any one of claims 1 to 11, wherein the tablet comprises one or more pharmaceutically acceptable excipients selected from mannitol, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate, or any combination thereof.

13. The tablet of claim 12, wherein the tablet comprises mannitol, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate.

14. The tablet of any one of claims 1 to 13, wherein the tablet comprises about 35 w / w% to about 45 w / w% of mannitol.

15. The tablet of any one of claims 1 to 13, wherein the tablet comprises about 40 w / w% to about 42 w / w% of mannitol.

16. The tablet of any one of claims 1 to 13, wherein the tablet comprises about 41.4 w / w% of mannitol.

17. The tablet of any one of claims 1 to 16, wherein the tablet comprises about 20 w / w% to about 25 w / w% of microcrystalline cellulose.

18. The tablet of any one of claims 1 to 16, wherein the tablet comprises about 22 w / w% to about 23 w / w% of microcrystalline cellulose.

19. The tablet of any one of claims 1 to 16, wherein the tablet comprises about 22.2 w / w% to about 22.4 w / w% of microcrystalline cellulose.

20. The tablet of any one of claims 1 to 16, wherein the tablet comprises about 22.2 w / w% to about 22.3 w / w% microcrystalline cellulose.

21. The tablet of any one of claims 1 to 16, wherein the tablet comprises about 22.288 w / w% microcrystalline cellulose.1572-WO-PCT / 35648-0367WO1 PATENT22. The tablet of any one of claims 1 to 16, wherein the tablet comprises about 22.3 w / w% to about 22.4 w / w% microcrystalline cellulose.

23. The tablet of any one of claims 1 to 16, wherein the tablet comprises about 22.3945 w / w% microcrystalline cellulose.

24. The tablet of any one of claims 1 to 23, wherein the tablet comprises about 5 w / w% to about 10 w / w% of croscarmellose sodium.

25. The tablet of any one of claims 1 to 23, wherein the tablet comprises about 7 w / w% to about 9 w / w% of croscarmellose sodium.

26. The tablet of any one of claims 1 to 23, wherein the tablet comprises about 8 w / w% of croscarmellose sodium.

27. The tablet of any one of claims 1 to 26, wherein the tablet comprises about 0.1 w / w% to about 2.0 w / w% of magnesium stearate.

28. The tablet of any one of claims 1 to 26, wherein the tablet comprises about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

29. The tablet of any one of claims 1 to 26, wherein the tablet comprises about 1.5 w / w% of magnesium stearate.

30. The tablet of claim 1, wherein the tablet comprises: about 18 w / w% to about 30 w / w% of the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.01 w / w% to about 2.0 w / w% of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 35 w / w% to about 45 w / w% of mannitol; about 20 w / w% to about 25 w / w% of microcrystalline cellulose;1572-WO-PCT / 35648-0367WO1 PATENT about 5 w / w% to about 10 w / w% of croscarmellose sodium; and about 0.1 w / w% to about 2.0 w / w% of magnesium stearate.

31. The tablet of claim 2, wherein the tablet comprises: about 26 w / w% to about 27 w / w% of the spray dried dispersion of the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.02 w / w% to about 0.2 w / w% of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 40 w / w% to about 42 w / w% of mannitol; about 22 w / w% to about 23 w / w% of microcrystalline cellulose; about 7 w / w% to about 9 w / w% of croscarmellose sodium; and about 1.0 w / w% to about 2.0 w / w% of magnesium stearate.

32. The tablet of claim 2, wherein the tablet comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.14 w / w% to about 0.15 w / w% of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41 w / w% to about 42 w / w% of mannitol; about 22.2 w / w% to about 22.3 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

33. The tablet of claim 2, wherein the tablet comprises: about 26.67 w / w% of the spray dried dispersion of the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.142 w / w% of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.40 w / w% of mannitol; about 22.288 w / w% microcrystalline cellulose;1572-WO-PCT / 35648-0367WO1 PATENT about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

34. The tablet of any one of claims 2 and 31 to 33, wherein the tablet comprises: about 20.46 w / w% of the sodium salt of the compound of Formula la; about 0.142 w / w% of the monohydrate of the compound of Formula Ila; about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.288 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

35. The tablet of claim 2, wherein the tablet comprises: about 26.6 w / w% to about 26.7 w / w% of the spray dried dispersion of the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.03 w / w% to about 0.04 w / w% of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41 w / w% to about 42 w / w% of mannitol; about 22.3 w / w% to about 22.4 w / w% of microcrystalline cellulose; about 7.9 w / w% to about 8.1 w / w% of croscarmellose sodium; and about 1.4 w / w% to about 1.6 w / w% of magnesium stearate.

36. The tablet of claim 2, wherein the tablet comprises: about 26.67 w / w% of the spray dried dispersion of the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.0355 w / w% of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.40 w / w% of mannitol; about 22.3945 w / w% microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and1572-WO-PCT / 35648-0367WO1 PATENT about 1.5 w / w% of magnesium stearate.

37. The tablet of any one of claims 2, 31, 35, and 36, wherein the tablet comprises: about 20.46 w / w% of the sodium salt of the compound of Formula la or lb; about 0.0355 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.395 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

38. The tablet of any one of claims 1 to 37, further comprising an outer film coat.

39. The tablet of claim 38, wherein the outer film coat comprises Opadry Clear.

40. The tablet of claim 38 or 39, wherein the outer film coat comprises about 0.5 w / w% to about 1.5 w / w% Opadry Clear.

41. The tablet of claim 38 or 39, wherein the outer film coat comprises about 1 w / w% Opadry Clear.

42. The tablet of any one of claims 38 to 41, wherein the outer film coat further comprises Opadry TF Pink or Opadry TF Gray.

43. The tablet of claim 42, wherein the outer film coat further comprises about 3.5 w / w% to about 4.5 w / w% Opadry TF Pink.

44. The tablet of claim 42, wherein the outer film coat comprises about 4 w / w% Opadry TF Pink.1572-WO-PCT / 35648-0367WO1 PATENT45. The tablet of claim 42, wherein the outer film coat comprises about 3.5 w / w% to about 4.5 w / w% Opadry TF Gray.

46. The tablet of claim 40, wherein the outer film coat comprises about 4 w / w% Opadry TF Gray.

47. The tablet of any one of claims 1 to 46, wherein the tablet comprises about 100 mg to about 500 mg of the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

48. The tablet of any one of claims 1 to 46, wherein the tablet comprises about 200 mg to about 400 mg of the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

49. The tablet of any one of claims 1 to 46, wherein the tablet comprises about 300 mg of the compound of Formula la, or a pharmaceutically acceptable salt, cocrystal, solvate, or combination thereof, on a free acid basis.

50. The tablet of any one of claims 1 to 49, wherein the tablet comprises about 0.1 mg to about 25 mg of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

51. The tablet of any one of claims 1 to 49, wherein the tablet comprises about 0.4 mg to about 22 mg of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

52. The tablet of any one of claims 1 to 49, wherein the tablet comprises about 0.1 mg to about 2.5 mg of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.1572-WO-PCT / 35648-0367WO1 PATENT53. The tablet of any one of claims 1 to 49, wherein the tablet comprises about 2.0 mg to about 2.2 mg of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

54. The tablet of any one of claims 1 to 49, wherein the tablet comprises about 2.1 mg to about 2.2 mg of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

55. The tablet of any one of claims 1 to 49, wherein the tablet comprises about 2.130 mg of the compound of Formula Ila, or a pharmaceutically acceptable salt, cocrystal, solvate, or combination thereof.

56. The tablet of any one of claims 1 to 49, wherein the tablet comprises about 2 mg of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis.

57. The tablet of any one of claims 1 to 49, wherein the tablet comprises about 0.4 mg to about 0.6 mg of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

58. The tablet of any one of claims 1 to 49, wherein the tablet comprises about 0.5 mg to about 0.6 mg of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

59. The tablet of any one of claims 1 to 49, wherein the tablet comprises about 0.5325 mg of the compound of Formula Ila, or a pharmaceutically acceptable salt, cocrystal, solvate, or combination thereof.

60. The tablet of any one of claims 1 to 49, wherein the tablet comprises about 0.5 mg of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free base basis.1572-WO-PCT / 35648-0367WO1 PATENT61. The tablet of any one of claims 1 to 46, wherein the tablet comprises: about 200 mg to about 400 mg of the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; and about 0.4 mg to about 22 mg of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

62. The tablet of any one of claims 1 to 46, wherein the tablet comprises: about 300 mg of the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis; and about 2.1 mg to about 2.2 mg of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

63. The tablet of any one of claims 1 to 46, wherein the tablet comprises: about 300 mg of the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis; and about 2.130 mg of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

64. The tablet of any one of claims 1 to 46, wherein the tablet comprises: about 300 mg of the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis; and about 0.5 mg to about 0.6 mg of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

65. The tablet of any one of claims 1 to 46, wherein the tablet comprises: about 300 mg of the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, on a free acid basis; and about 0.5325 mg of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

66. The tablet of any one of claims 1 to 65, wherein the tablet is about 1400 mg to about 1600 mg.1572-WO-PCT / 35648-0367WO1 PATENT67. The tablet of any one of claims 1 to 65, wherein the tablet is about 1500 mg.

68. The tablet of any one of claims 1 to 67, wherein the tablet is suitable for oral administration.

69. The tablet of any one of claims 1 to 34, 36, and 38 to 68, wherein the tablet comprises a pharmaceutically acceptable salt of the compound of Formula la.

70. The tablet of any one of claims 1 to 34, 36, and 38 to 69, wherein the tablet comprises a sodium salt of the compound of Formula la.

71. The tablet of any one of claims 1 to 70, wherein the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, is a compound of Formula lb:or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

72. The tablet of claim 71, wherein the tablet comprises a pharmaceutically acceptable salt of the compound of Formula lb.

73. The tablet of claim 71 or 72, wherein the tablet comprises a sodium salt of the compound of Formula lb.1572-WO-PCT / 35648-0367WO1 PATENT74. The tablet of any one of claims 1 to 34, 36, and 38 to 73, wherein the tablet comprises a solvate of the compound of Formula Ila.

75. The tablet of any one of claims 1 to 34, 36, and 38 to 74, wherein the tablet comprises a monohydrate of the compound of Formula Ila.

76. The tablet of any one of claims 1 to 75, wherein the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, is alib or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

77. The tablet of claim 76, wherein the tablet comprises a solvate of the compound of Formula lib.

78. The tablet of claim 76 or 77, wherein the tablet comprises a monohydrate of the compound of Formula lib.

79. A method of treating HIV in a patient, comprising administering to the patient a tablet of any one of claims 1 to 78.

80. The method of claim 79, wherein the method comprises oral administration of the tablet.

81. The method of claim 79 or 80, wherein the tablet comprises: about 26.67 w / w% of the spray dried dispersion of the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof;1572-WO-PCT / 35648-0367WO1 PATENT about 0.142 w / w% of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.40 w / w% of mannitol; about 22.288 w / w% microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

82. The method of any one of claims 79 to 81, wherein the tablet comprises: about 20.46 w / w% of the sodium salt of the compound of Formula la; about 0.142 w / w% of the monohydrate of the compound of Formula Ila; about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.288 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

83. The method of claim 79 or 80, wherein the tablet comprises: about 26.67 w / w% of the spray dried dispersion of the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.0355 w / w% of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.4 w / w% of mannitol; about 22.3945 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

84. The method of any one of claims 79, 80, and 83, wherein the tablet comprises: about 20.46 w / w% of the sodium salt of the compound of Formula la or lb; about 0.0355 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4.88 w / w% of copovidone;1572-WO-PCT / 35648-0367WO1 PATENT about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.395 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

85. The method of any one of claims 79 to 84, which is a method of treating HIV.

86. The method of any one of claims 79 to 84, wherein the tablet is administered as a monotherapy.

87. The method of any one of claims 79 to 86, wherein the method comprises orally administering to the patient an initiation dosage of the tablet for a first period of time; and orally administering to the patient one or more maintenance dosages of the tablet for a second period of time, wherein the second period of time occurs after the first period of time.

88. The method of claim 87, wherein the first period of time is two days.

89. The method of claim 87 or 88, wherein the initiation dosage comprises orally administering to the patient two tablets on day 1, and orally administering to the patient two tablets on day 2.

90. The method of any one of claims 87 to 89, wherein each tablet of the initiation dosage comprises: about 26.67 w / w% of the spray dried dispersion of the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.0355 w / w% of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.4 w / w% of mannitol; about 22.3945 w / w% of microcrystalline cellulose;1572-WO-PCT / 35648-0367WO1 PATENT about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

91. The method of any one of claims 87 to 90, wherein each tablet of the initiation dosage comprises: about 20.46 w / w% of the sodium salt of the compound of Formula la or lb; about 0.0355 w / w% of the monohydrate of the compound of Formula Ila or lib; about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.395 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

92. The method of any one of claims 87 to 91, wherein the second period of time begins about one week after the beginning of the first period of time.

93. The method of any one of claims 87 to 92, wherein each maintenance dosage comprises orally administering to the patient one tablet, once weekly.

94. The method of any one of claims 87 to 93, wherein each tablet of the maintenance dosage comprises: about 26.67 w / w% of the spray dried dispersion of the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 0.142 w / w% of the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof; about 41.40 w / w% of mannitol; about 22.288 w / w% microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.1572-WO-PCT / 35648-0367WO1 PATENT95. The method of any one of claims 87 to 94, wherein each tablet of the maintenance dosage comprises: about 20.46 w / w% of the sodium salt of the compound of Formula la; about 0.142 w / w% of the monohydrate of the compound of Formula Ila; about 4.88 w / w% of copovidone; about 1.33 w / w% of pol oxamer 407; about 41.40 w / w% of mannitol; about 22.288 w / w% of microcrystalline cellulose; about 8.0 w / w% of croscarmellose sodium; and about 1.5 w / w% of magnesium stearate.

96. The method of any one of claims 87 to 95, wherein if the patient misses a maintenance dosage; and wherein between about 7 days to about 16 days have elapsed since administration of a prior maintenance dosage; the method further comprises restarting administration of the one or more maintenance dosages.

97. The method of any one of claims 87 to 95, wherein if the patient misses a maintenance dosage; and wherein between about 8 days to about 15 days have elapsed since administration of a prior maintenance dosage; the method further comprises restarting administration of the one or more maintenance dosages.

98. The method of any one of claims 87 to 95, wherein if the patient misses a maintenance dosage; and wherein between about 8 days to about 14 days have elapsed since administration of a prior maintenance dosage; the method further comprises restarting administration of the one or more maintenance dosages.1572-WO-PCT / 35648-0367WO1 PATENT99. The method of any one of claims 79 to 81, 83, 85 to 90, 92 to 94, and 96 to 98, wherein the tablet comprises a pharmaceutically acceptable salt of the compound of Formula la.

100. The method of any one of claims 79 to 81, 83, 85 to 90, 92 to 94, and 96 to 99, wherein the tablet comprises a sodium salt of the compound of Formula la.

101. The method of any one of claims 79 to 100, wherein the compound of Formula la, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, is a compound of Formula lb:or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

102. The method of claim 101, wherein the tablet comprises a pharmaceutically acceptable salt of the compound of Formula lb.

103. The method of claim 101 or 102, wherein the tablet comprises a sodium salt of the compound of Formula lb.

104. The method of any one of claims 79 to 81, 83, 85 to 90, 92 to 94, and 96 to103, wherein the tablet comprises a solvate of the compound of Formula Ila.

105. The method of any one of claims 79 to 81, 83, 85 to 90, 92 to 94, and 96 to104, wherein the tablet comprises a monohydrate of the compound of Formula Ila.1572-WO-PCT / 35648-0367WO1 PATENT106. The method of any one of claims 79 to 105, wherein the compound of Formula Ila, or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof, is a compound of Formula lib :Hb or a pharmaceutically acceptable salt, co-crystal, solvate, or combination thereof.

107. The method of claim 106, wherein the tablet comprises a solvate of the compound of Formula lib.

108. The method of claim 106 or 107, wherein the tablet comprises a monohydrate of the compound of Formula lib.

109. A method of treating HIV in a patient, comprising: i) administering to the patient an initiation dose comprising two tablets on day 1, and two tablets on day 2, wherein each tablet of the initiation dose comprises: about 300 mg of the compound of Formula lb:1572-WO-PCT / 35648-0367WO1 PATENT on a free acid basis; about 0.5 mg of the compound of Formula lib :lib on a free base basis; about 621 mg of mannitol; about 335.9175 mg of microcrystalline cellulose; about 120 mg croscarmellose sodium; and about 22.5 mg magnesium stearate; and ii) administering to the patient a maintenance dose comprising one tablet, once weekly, beginning on day 8, wherein the tablet comprises: about 300 mg of the compound of Formula lb, on a free acid basis; about 2.0 mg of the compound of Formula Hb, on a free base basis; about 621 mg of mannitol; about 334.32 mg of microcrystalline cellulose; about 120 mg croscarmellose sodium; and about 22.5 mg magnesium stearate; wherein if the patient misses a maintenance dosage; and wherein between about 7 days to about 16 days have elapsed since administration of a prior maintenance dosage; the method further comprises restarting administration of the one or more maintenance dosages of step (ii) as soon as possible after the missed dose.

110. A method of treating HIV in a patient, comprising: i) administering to the patient an initiation dose comprising two tablets on day 1, and two tablets on day 2, wherein each tablet of the initiation dose comprises:1572-WO-PCT / 35648-0367WO1 PATENT about 300 mg of the compound of Formula lb:lb on a free acid basis; about 0.5 mg of the compound of Formula lib :lib on a free base basis; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407; about 621 mg of mannitol; about 335.92 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; about 22.5 mg of magnesium stearate; and ii) administering to the patient a maintenance dose comprising one tablet, once weekly, beginning on day 8, wherein the tablet comprises: about 300 mg of the compound of Formula lb, on a free acid basis; about 2.0 mg of the compound of Formula lib, on a free base basis; about 73.2 mg of copovidone; about 19.95 mg of poloxamer 407;1572-WO-PCT / 35648-0367WO1 PATENT about 621 mg of mannitol; about 334.32 mg of microcrystalline cellulose; about 120 mg of croscarmellose sodium; about 22.5 mg of magnesium stearate; wherein if the patient misses a maintenance dosage; and wherein between about 7 days to about 16 days have elapsed since administration of a prior maintenance dosage; the method further comprises restarting administration of the one or more maintenance dosages of step (ii) as soon as possible after the missed dose.

Images